|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
NZ595736A
(en)
|
2005-12-02 |
2013-05-31 |
Sinai School Medicine |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
CN101925611A
(zh)
*
|
2007-11-21 |
2010-12-22 |
安姆根有限公司 |
Wise结合剂和表位
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
ES2741730T3
(es)
|
2008-05-19 |
2020-02-12 |
Advaxis Inc |
Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
|
|
CN102369285B
(zh)
|
2008-11-12 |
2014-06-18 |
默沙东公司 |
用于增强的抗-IGF1R表达的βGl-IgG内含子
|
|
ES2593027T3
(es)
|
2009-03-30 |
2016-12-05 |
Eisai R&D Management Co., Ltd. |
Composición liposomal
|
|
US20120302737A1
(en)
|
2009-09-16 |
2012-11-29 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
EP2482849B1
(en)
|
2009-09-30 |
2018-06-06 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
HRP20171653T1
(hr)
*
|
2009-11-24 |
2017-12-15 |
Medimmune Limited |
Vezna sredstva koja služe ciljano protiv b7-h1
|
|
EP2516624B1
(en)
*
|
2009-12-23 |
2020-02-05 |
Merck Sharp & Dohme Corp. |
Cell line 3m
|
|
CN102892786B
(zh)
*
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
WO2012018538A2
(en)
*
|
2010-07-26 |
2012-02-09 |
Schering Corporation |
Bioassays for determining pd-1 modulation
|
|
JP5981436B2
(ja)
|
2010-10-01 |
2016-08-31 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
|
|
CA2817448C
(en)
|
2010-12-23 |
2019-01-22 |
F. Hoffmann-La Roche Ag |
Binding agent
|
|
CA2817455C
(en)
*
|
2010-12-23 |
2019-04-16 |
F. Hoffmann-La Roche Ag |
Detection of a polypeptide dimer by a bivalent binding agent
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
ES2605493T3
(es)
|
2010-12-23 |
2017-03-14 |
F. Hoffmann-La Roche Ag |
Detección de un polipéptido modificado post-traduccionalmente mediante un agente ligante bivalente
|
|
EP3332804A1
(en)
|
2011-03-11 |
2018-06-13 |
Advaxis, Inc. |
Listeria-based adjuvants
|
|
SI2691112T1
(en)
*
|
2011-03-31 |
2018-07-31 |
Merck Sharp & Dohme Corp. |
STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
|
|
ES2669310T3
(es)
*
|
2011-04-20 |
2018-05-24 |
Medimmune, Llc |
Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
|
|
JP6240063B2
(ja)
|
2011-04-28 |
2017-11-29 |
ザ ブロード インスティテュート, インコーポレイテッド |
ヒストンデアセチラーゼ阻害剤
|
|
RU2670745C9
(ru)
|
2011-05-24 |
2018-12-13 |
Бионтех Рна Фармасьютикалс Гмбх |
Индивидуализированные противоопухолевые вакцины
|
|
WO2013003555A1
(en)
|
2011-06-28 |
2013-01-03 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
|
PT3409278T
(pt)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de proteína cinase heterocíclicos
|
|
WO2013022091A1
(ja)
|
2011-08-11 |
2013-02-14 |
小野薬品工業株式会社 |
Pd-1アゴニストからなる自己免疫疾患治療剤
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
WO2013078223A1
(en)
*
|
2011-11-23 |
2013-05-30 |
Children's Hospital & Research Center Oakland |
Anti-factor h binding protein antibodies and methods of use thereof
|
|
GB201120779D0
(en)
|
2011-12-02 |
2012-01-11 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
|
US20150071987A1
(en)
*
|
2012-02-03 |
2015-03-12 |
Emory University |
Immunostimulatory compositions, particles, and uses related thereto
|
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック, インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
|
WO2013126810A1
(en)
*
|
2012-02-24 |
2013-08-29 |
Stem Centrx, Inc. |
Anti sez6 antibodies and methods of use
|
|
EP2825195A4
(en)
|
2012-03-12 |
2015-10-07 |
Advaxis Inc |
INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
CN107652289B
(zh)
|
2012-06-13 |
2020-07-21 |
因塞特控股公司 |
作为fgfr抑制剂的取代的三环化合物
|
|
CN104395340B9
(zh)
*
|
2012-06-27 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
包含至少两个不同靶向实体的定制选择性和多特异性治疗分子的方法及其用途
|
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CA2880117C
(en)
|
2012-07-27 |
2021-04-06 |
The Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
|
JP6457940B2
(ja)
|
2012-08-30 |
2019-01-23 |
アムジエン・インコーポレーテツド |
単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
|
|
BR112015003938A2
(pt)
|
2012-09-14 |
2018-09-04 |
Hoffmann La Roche |
métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico
|
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
EP2925348B1
(en)
|
2012-11-28 |
2019-03-06 |
BioNTech RNA Pharmaceuticals GmbH |
Individualized vaccines for cancer
|
|
EP2928474B1
(en)
|
2012-12-07 |
2018-11-14 |
ChemoCentryx, Inc. |
Diazole lactams
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
AR093984A1
(es)
*
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
WO2014121085A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Pd-l1 and pd-l2-based fusion proteins and uses thereof
|
|
WO2014130657A1
(en)
|
2013-02-20 |
2014-08-28 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗-cd123嵌合抗原受體工程化t細胞之初級人類白血病有效靶向
|
|
EP2958571B1
(en)
*
|
2013-02-21 |
2024-04-10 |
Michele Maio |
Dna hypomethylating agents for cancer therapy
|
|
EP2958588B1
(en)
|
2013-02-22 |
2017-08-23 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
CN105163745B
(zh)
*
|
2013-03-01 |
2020-06-12 |
美国卫生和人力服务部 |
从外周血中产生肿瘤反应性t细胞富集群的方法
|
|
EA038981B1
(ru)
|
2013-03-14 |
2021-11-17 |
Икан Скул Оф Медсин Эт Маунт Синай |
Вирусы болезни ньюкасла и их применение
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
|
US20160084839A1
(en)
*
|
2013-04-02 |
2016-03-24 |
Marisa Dolled-Filhart |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
|
WO2014168941A1
(en)
|
2013-04-09 |
2014-10-16 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
|
CN106211758B
(zh)
|
2013-04-09 |
2021-03-23 |
北京强新生物科技有限公司 |
2-乙酰基萘并[2,3-b]呋喃-4,9-二酮用于治疗癌症的用途
|
|
JP6449244B2
(ja)
|
2013-04-19 |
2019-01-09 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Fgfr抑制剤としての二環式複素環
|
|
RU2723050C2
(ru)
*
|
2013-05-02 |
2020-06-08 |
Анаптисбайо, Инк. |
Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1)
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
WO2014183071A2
(en)
|
2013-05-10 |
2014-11-13 |
Whitehead Institute For Biomedical Research |
In vitro production of red blood cells with sortaggable proteins
|
|
WO2014183066A2
(en)
|
2013-05-10 |
2014-11-13 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
CA2913977C
(en)
*
|
2013-05-31 |
2022-11-29 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
ES2822665T3
(es)
*
|
2013-05-31 |
2021-05-04 |
Merck Sharp & Dohme |
Terapias de combinación para el cáncer
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
AU2014296887A1
(en)
|
2013-08-02 |
2016-01-28 |
Aduro Biotech Holdings, Europe B.V. |
Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
|
|
KR102457731B1
(ko)
|
2013-08-08 |
2022-10-21 |
싸이튠 파마 |
병용 약학 조성물
|
|
BR112016002614B8
(pt)
|
2013-08-08 |
2023-11-07 |
Hopitaux Paris Assist Publique |
Imunocitoquina e composição farmacêutica
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
ES2827679T3
(es)
|
2013-08-20 |
2021-05-24 |
Merck Sharp & Dohme |
Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib
|
|
CU24345B1
(es)
|
2013-09-06 |
2018-05-08 |
Aurigene Discovery Tech Ltd |
Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
|
|
HRP20181052T1
(hr)
|
2013-09-06 |
2018-09-07 |
Aurigene Discovery Technologies Limited |
Derivati 1,2,4-oksadiazola kao imunomodulatori
|
|
EA201891818A3
(ru)
|
2013-09-06 |
2019-03-29 |
Ауриген Дискавери Текнолоджиз Лимитед |
Способ получения соединений, используемых при получении циклических пептидомиметических соединений
|
|
WO2015036394A1
(en)
*
|
2013-09-10 |
2015-03-19 |
Medimmune Limited |
Antibodies against pd-1 and uses thereof
|
|
IL296026B2
(en)
*
|
2013-09-13 |
2024-10-01 |
Beigene Switzerland Gmbh |
Anti-pd1 antibodies and their use as therapeutics and diagnostics
|
|
SI3508502T1
(sl)
|
2013-09-20 |
2023-07-31 |
Bristol-Myers Squibb Company |
Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
CN104558177B
(zh)
*
|
2013-10-25 |
2020-02-18 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
|
|
CN104560884A
(zh)
*
|
2013-10-25 |
2015-04-29 |
苏州思坦维生物技术有限责任公司 |
拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及分泌它的杂交瘤细胞系与用途
|
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
|
IL292510A
(en)
*
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
US9457019B2
(en)
*
|
2013-11-07 |
2016-10-04 |
Deciphera Pharmaceuticals, Llc |
Methods for inhibiting tie-2 kinase useful in the treatment of cancer
|
|
WO2015073746A2
(en)
|
2013-11-13 |
2015-05-21 |
Whitehead Institute For Biomedical Research |
18f labeling of proteins using sortases
|
|
JP2016537345A
(ja)
|
2013-11-13 |
2016-12-01 |
ノバルティス アーゲー |
免疫応答を増強するためのmTOR阻害剤
|
|
EP3079772B1
(en)
|
2013-12-10 |
2020-02-05 |
Merck Sharp & Dohme Corp. |
Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
|
|
US20160303231A1
(en)
*
|
2013-12-11 |
2016-10-20 |
Robert Iannone |
Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
|
|
DK3081576T3
(da)
*
|
2013-12-12 |
2019-10-21 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf
|
|
US20160304969A1
(en)
|
2013-12-17 |
2016-10-20 |
Merck Sharp & Dohme Corp. |
Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
|
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
|
SG11201604815RA
(en)
|
2013-12-19 |
2016-07-28 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
AU2014368449C1
(en)
|
2013-12-20 |
2021-05-06 |
Intervet International B.V. |
Canine antibodies with modified CH2-CH3 sequences
|
|
GB201322725D0
(en)
|
2013-12-20 |
2014-02-05 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
|
US20170106065A1
(en)
*
|
2013-12-31 |
2017-04-20 |
Bavarian Nordic A/S |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
|
|
EP3092004A4
(en)
*
|
2014-01-06 |
2017-02-22 |
The Trustees Of The University Of Pennsylvania |
Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
|
|
HUE057917T2
(hu)
*
|
2014-01-15 |
2022-06-28 |
Kadmon Corp Llc |
Immunmodulátor szerek
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
WO2015119923A1
(en)
|
2014-02-04 |
2015-08-13 |
Pfizer Inc. |
Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer
|
|
WO2015119930A1
(en)
|
2014-02-04 |
2015-08-13 |
Pfizer Inc. |
Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
|
|
KR20160108568A
(ko)
*
|
2014-02-04 |
2016-09-19 |
인사이트 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
|
|
JP6857498B2
(ja)
|
2014-02-27 |
2021-04-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
癌を処置するための併用方法
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
CN106255510A
(zh)
|
2014-03-05 |
2016-12-21 |
百时美施贵宝公司 |
使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌
|
|
WO2015135558A1
(en)
|
2014-03-12 |
2015-09-17 |
Curevac Gmbh |
Combination of vaccination and ox40 agonists
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
KR20230097209A
(ko)
|
2014-03-12 |
2023-06-30 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
RS59853B1
(sr)
|
2014-03-14 |
2020-02-28 |
Novartis Ag |
Molekuli anti-lag-3 antitela i njihove upotrebe
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
TWI714525B
(zh)
|
2014-03-24 |
2021-01-01 |
瑞士商諾華公司 |
用於治療細菌感染之單內醯胺(monobactam)有機化合物
|
|
SG11201606909RA
(en)
|
2014-04-07 |
2016-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
WO2015160933A1
(en)
|
2014-04-15 |
2015-10-22 |
Sabic Global Technologies B.V. |
Methods of manufacture of polyetherimides
|
|
WO2015176033A1
(en)
|
2014-05-15 |
2015-11-19 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
KR102535283B1
(ko)
|
2014-05-23 |
2023-05-22 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암의 치료를 위한 조합 요법
|
|
CA2947939A1
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
|
RS59643B1
(sr)
|
2014-06-06 |
2020-01-31 |
Bristol Myers Squibb Co |
Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
|
|
WO2015195163A1
(en)
*
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
JP6526189B2
(ja)
|
2014-07-03 |
2019-06-05 |
ベイジーン リミテッド |
抗pd−l1抗体並びにその治療及び診断のための使用
|
|
CA2954446A1
(en)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
CN106999577B
(zh)
|
2014-07-16 |
2021-12-21 |
特兰斯吉恩股份有限公司 |
溶瘤病毒和免疫检查点调节因子组合
|
|
JP6895374B2
(ja)
|
2014-07-16 |
2021-06-30 |
トランジェーヌTransgene |
免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
|
|
KR20170052569A
(ko)
|
2014-07-18 |
2017-05-12 |
어드박시스, 인크. |
전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
KR102524920B1
(ko)
|
2014-07-22 |
2023-04-25 |
아폴로믹스 인코포레이티드 |
항-pd-1 항체
|
|
CN105330740B
(zh)
*
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
RU2722212C9
(ru)
|
2014-08-05 |
2020-07-23 |
СиБи ТЕРЕПЬЮТИКС, ИНК. |
Анти-pd-l1 антитела
|
|
US9982053B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
JP2017523213A
(ja)
|
2014-08-06 |
2017-08-17 |
ノバルティス アーゲー |
抗菌薬としてのキノロン誘導体
|
|
EP3177321B1
(en)
*
|
2014-08-08 |
2020-11-25 |
Oncoquest Pharmaceuticals Inc. |
Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer
|
|
HUE059131T2
(hu)
|
2014-08-11 |
2022-10-28 |
Acerta Pharma Bv |
BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
CN106659780A
(zh)
*
|
2014-08-14 |
2017-05-10 |
豪夫迈·罗氏有限公司 |
活化人cd40的抗体和针对人pd‑l1的抗体的组合疗法
|
|
WO2016028896A1
(en)
|
2014-08-19 |
2016-02-25 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
WO2016032927A1
(en)
|
2014-08-25 |
2016-03-03 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
|
HRP20190881T1
(hr)
|
2014-08-28 |
2019-07-12 |
Halozyme, Inc. |
Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
US9535074B2
(en)
|
2014-09-08 |
2017-01-03 |
Merck Sharp & Dohme Corp. |
Immunoassay for soluble PD-L1
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
ES2825576T3
(es)
|
2014-09-16 |
2021-05-17 |
Innate Pharma |
Neutralización de rutas inhibidoras en linfocitos
|
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
EA034921B1
(ru)
*
|
2014-09-28 |
2020-04-07 |
Зе Реджентс Оф Зе Юниверсити Оф Калифорния |
Модуляция стимулирующих и нестимулирующих миелоидных клеток
|
|
ES2853823T3
(es)
|
2014-09-30 |
2021-09-17 |
Intervet Int Bv |
Anticuerpos de PD-L1 que se unen a PD-L1 canino
|
|
US10053683B2
(en)
|
2014-10-03 |
2018-08-21 |
Whitehead Institute For Biomedical Research |
Intercellular labeling of ligand-receptor interactions
|
|
CA2963281A1
(en)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Combination therapies
|
|
IL279420B2
(en)
|
2014-10-08 |
2024-09-01 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP4029508A1
(en)
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonists and checkpoint inhibitors
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
|
CA3203273A1
(en)
|
2014-10-14 |
2016-04-21 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
RS61602B1
(sr)
|
2014-10-29 |
2021-04-29 |
Five Prime Therapeutics Inc |
Kombinovana terapija za kancer
|
|
US11236139B2
(en)
|
2014-11-05 |
2022-02-01 |
The Regents Of The University Of California |
Combination immunotherapy
|
|
ES2987508T3
(es)
|
2014-11-14 |
2024-11-15 |
Novartis Ag |
Conjugados de anticuerpos y fármacos
|
|
EP3220927B1
(en)
|
2014-11-20 |
2022-01-05 |
Promega Corporation |
Systems and methods for assessing modulators of immune checkpoints
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
MX2017007097A
(es)
|
2014-12-04 |
2017-09-05 |
Bristol Myers Squibb Co |
Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
|
|
IL307913A
(en)
|
2014-12-04 |
2023-12-01 |
Janssen Biotech Inc |
Anti-CD38 antibodies for the treatment of acute myeloid leukemia
|
|
WO2016089797A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
US10086000B2
(en)
|
2014-12-05 |
2018-10-02 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
|
WO2016089830A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
EP3227337A1
(en)
|
2014-12-05 |
2017-10-11 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
|
CN107109700A
(zh)
|
2014-12-09 |
2017-08-29 |
默沙东公司 |
用于推导对pd‑1拮抗剂的反应的基因特征生物标志物的系统和方法
|
|
JP6697466B2
(ja)
|
2014-12-16 |
2020-05-20 |
ノバルティス アーゲー |
LpxC阻害剤としてのイソオキサゾールヒドロキサム酸化合物
|
|
IL308119B2
(en)
|
2014-12-18 |
2025-11-01 |
Amgen Inc |
Stable frozen herpes simplex virus formulation
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
US11639385B2
(en)
|
2014-12-22 |
2023-05-02 |
Pd-1 Acquisition Group, Llc |
Anti-PD-1 antibodies
|
|
CA3175979A1
(en)
|
2014-12-22 |
2016-06-30 |
Pd-1 Acquisition Group, Llc |
Anti-pd-1 antibodies
|
|
CN105820247A
(zh)
*
|
2014-12-31 |
2016-08-03 |
三生国健药业(上海)股份有限公司 |
一种筛选pd-1抗体的方法
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
GB201500374D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|
|
HK1247861A1
(zh)
|
2015-01-30 |
2018-10-05 |
President And Fellows Of Harvard College |
用於癌症治疗的肿瘤周围和肿瘤内部材料
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
WO2016128542A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
ES2751669T3
(es)
|
2015-02-20 |
2020-04-01 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores FGFR
|
|
RU2714233C2
(ru)
|
2015-02-26 |
2020-02-13 |
Мерк Патент Гмбх |
Ингибиторы pd-1 / pd-l1 для лечения рака
|
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
|
BR112017018872A2
(pt)
|
2015-03-04 |
2018-05-29 |
Eisai R&D Man Co Ltd |
combinação de um antagonista pd-1 e eribulina para tratamento de câncer
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
KR20170129802A
(ko)
|
2015-03-10 |
2017-11-27 |
아두로 바이오테크, 인코포레이티드 |
"인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법
|
|
KR102708045B1
(ko)
|
2015-03-10 |
2024-09-23 |
오리진 온콜로지 리미티드 |
면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
|
|
MX2017011644A
(es)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
|
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
DK3274370T3
(da)
|
2015-03-23 |
2020-02-17 |
Bayer Pharma AG |
Anti-ceacam6-antistoffer og anvendelser deraf
|
|
EP3277320A4
(en)
|
2015-03-30 |
2018-08-01 |
Stcube, Inc. |
Antibodies specific to glycosylated pd-l1 and methods of use thereof
|
|
US11933786B2
(en)
|
2015-03-30 |
2024-03-19 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-L1 and methods of use thereof
|
|
FI3277321T3
(fi)
|
2015-04-01 |
2024-10-31 |
Anaptysbio Inc |
T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
|
|
CN116327915A
(zh)
|
2015-04-03 |
2023-06-27 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
|
EP3280795B1
(en)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
ES2844049T3
(es)
|
2015-04-07 |
2021-07-21 |
Cytlimic Inc |
Adyuvante para vacunas contra el cáncer
|
|
RS60753B1
(sr)
|
2015-04-17 |
2020-10-30 |
Bristol Myers Squibb Co |
Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
|
|
EP3283882B2
(en)
|
2015-04-17 |
2024-10-16 |
Merck Sharp & Dohme LLC |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
|
CN118726268A
(zh)
|
2015-04-17 |
2024-10-01 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3288982A1
(en)
|
2015-04-28 |
2018-03-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
|
KR20250107941A
(ko)
|
2015-04-28 |
2025-07-14 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
|
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
|
CA2984975A1
(en)
|
2015-05-06 |
2016-11-10 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
|
CN104987421A
(zh)
*
|
2015-05-13 |
2015-10-21 |
北京比洋生物技术有限公司 |
抗ctla-4和pd-1的双重可变结构域免疫球蛋白
|
|
TR201911032T4
(tr)
|
2015-05-18 |
2019-08-21 |
Tolero Pharmaceuticals Inc |
Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
|
|
MY198983A
(en)
|
2015-05-20 |
2023-10-06 |
Janssen Biotech Inc |
Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
|
|
PT3297438T
(pt)
|
2015-05-21 |
2022-01-25 |
Chemocentryx Inc |
Moduladores de ccr2
|
|
ES2889906T3
(es)
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
|
WO2016189055A1
(en)
|
2015-05-27 |
2016-12-01 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of cancer
|
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
ES2985394T3
(es)
|
2015-05-29 |
2024-11-05 |
Merck Sharp & Dohme Llc |
Combinación de un antagonista de PD-1 y un oligonucleótido de tipo CpG-C para el tratamiento del cáncer
|
|
WO2016196218A1
(en)
|
2015-05-31 |
2016-12-08 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
TW201717935A
(zh)
|
2015-06-03 |
2017-06-01 |
波士頓生醫公司 |
用於治療癌症的組成物和方法
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
CN105061597B
(zh)
*
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
一种抗pd-1的单克隆抗体及其获得方法
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
US20180141991A1
(en)
|
2015-06-12 |
2018-05-24 |
Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital |
Methods and polypeptides for modulation of immunoresponse
|
|
EP3307778A1
(en)
|
2015-06-12 |
2018-04-18 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
|
MX390878B
(es)
|
2015-06-16 |
2025-03-21 |
Merck Patent Gmbh |
Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
|
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
|
CN108337890B
(zh)
*
|
2015-06-23 |
2021-10-15 |
纪念斯隆-凯特琳癌症中心 |
新型pd-1免疫调节剂
|
|
HUE066300T2
(hu)
|
2015-06-24 |
2024-07-28 |
Janssen Biotech Inc |
Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
|
|
PT3319635T
(pt)
|
2015-06-24 |
2021-07-07 |
Immodulon Therapeutics Ltd |
Um inibidor de ponto de verificação e uma micobactéria de célula inteira para utilização em terapêutica do cancro
|
|
BR112017028530A2
(pt)
|
2015-07-02 |
2018-08-28 |
Celgene Corp |
terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
HK1250033A1
(zh)
|
2015-07-13 |
2018-11-23 |
Cytomx Therapeutics Inc. |
抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
|
|
EP3322731B1
(en)
|
2015-07-14 |
2021-01-13 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
|
|
CA2991628C
(en)
|
2015-07-16 |
2020-04-07 |
Bioxcel Therapeutics, Inc. |
A novel approach for treatment of cancer using immunomodulation
|
|
WO2017009843A2
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
Compositions, articles of manufacture and methods for treating cancer
|
|
TWI859112B
(zh)
|
2015-07-21 |
2024-10-21 |
瑞士商諾華公司 |
改良免疫細胞之功效及擴展之方法
|
|
EP4378957A3
(en)
|
2015-07-29 |
2024-08-07 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CR20200423A
(es)
*
|
2015-07-30 |
2021-01-20 |
Macrogenics Inc |
Moléculas de unión a pd-1 y métodos de uso de las mismas (divisional 2018-0062)
|
|
US10660954B2
(en)
|
2015-07-31 |
2020-05-26 |
University Of Florida Research Foundation, Incorporated |
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
|
|
CN106397592A
(zh)
*
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
CA2994394A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Constellation Pharmaceuticals, Inc. |
Ezh2 inhibitors and modulation of regulatory t-cell function
|
|
WO2017021911A1
(en)
*
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
EP3331901A1
(en)
|
2015-08-07 |
2018-06-13 |
Pieris Pharmaceuticals GmbH |
Novel fusion polypeptide specific for lag-3 and pd-1
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
PT3334763T
(pt)
*
|
2015-08-11 |
2024-10-28 |
Wuxi Biologics Ireland Ltd |
Novos anticorpos anti-pd-1
|
|
WO2017027645A1
(en)
|
2015-08-13 |
2017-02-16 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
AR105654A1
(es)
*
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
US11385231B2
(en)
|
2015-08-27 |
2022-07-12 |
Inserm (Institut National De La Sante Et De La Recherche Scientifique) |
Methods for predicting the survival time of patients suffering from a lung cancer
|
|
WO2017040790A1
(en)
|
2015-09-01 |
2017-03-09 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
DK3345618T3
(da)
|
2015-09-03 |
2022-02-07 |
Ono Pharmaceutical Co |
Middel til forbedring af immunitet over for cancer ved hjælp af allergin-1-antagonist
|
|
US20170114098A1
(en)
|
2015-09-03 |
2017-04-27 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
EP3350183B1
(en)
|
2015-09-14 |
2025-04-02 |
Twelve Therapeutics, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
US9995753B2
(en)
|
2015-09-25 |
2018-06-12 |
Merck Sharp & Dohme Corp. |
Anti-pembrolizumab antibodies
|
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
|
HK1251158A1
(zh)
*
|
2015-09-29 |
2019-01-25 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
WO2017055484A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining the metabolic status of lymphomas
|
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
|
JP6952028B2
(ja)
*
|
2015-09-29 |
2021-10-20 |
シャンハイ チャンジアン バイオテクノロジー カンパニー リミテッド |
Pd−1抗体およびその使用
|
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
JP2018529351A
(ja)
|
2015-09-30 |
2018-10-11 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒトcd40に特異的に結合するアンタゴニスト抗体及び使用方法
|
|
JP2018530550A
(ja)
|
2015-10-01 |
2018-10-18 |
ギリアド サイエンシズ, インコーポレイテッド |
癌を治療するためのbtk阻害剤とチェックポイント阻害剤との組合せ
|
|
RU2729379C1
(ru)
|
2015-10-01 |
2020-08-06 |
Потенза Терапевтикс, Инк. |
Анти-tigit антигенсвязывающие белки и способы их применения
|
|
US12048753B2
(en)
|
2015-10-01 |
2024-07-30 |
Whitehead Institute For Biomedical Research |
Labeling of antibodies
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
DK3356404T3
(da)
|
2015-10-02 |
2021-10-25 |
Hoffmann La Roche |
Anti-pd1-antistoffer og fremgangsmåder til anvendelse
|
|
JP6622392B2
(ja)
|
2015-10-02 |
2019-12-18 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1とtim3に特異的な二重特異性抗体
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
HK1251475A1
(zh)
|
2015-10-08 |
2019-02-01 |
Macrogenics, Inc. |
用於癌症治疗的联合疗法
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
EP3362074B1
(en)
|
2015-10-16 |
2023-08-09 |
President and Fellows of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
|
JP6855469B2
(ja)
|
2015-10-16 |
2021-04-07 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
消化器標的療法のための処方物を調製するための工程
|
|
US20180318365A1
(en)
|
2015-10-19 |
2018-11-08 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
CN105175544B
(zh)
*
|
2015-10-20 |
2021-04-09 |
安徽瀚海博兴生物技术有限公司 |
一种抗pd-1人源化单克隆抗体及其应用
|
|
CN105175545B
(zh)
*
|
2015-10-20 |
2019-01-25 |
安徽瀚海博兴生物技术有限公司 |
一种抗vegf-抗pd-1双功能抗体及其应用
|
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
|
MX2018005517A
(es)
|
2015-11-02 |
2018-11-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
|
|
SI3370733T1
(sl)
|
2015-11-02 |
2021-11-30 |
Board Of Regents The University Of Texas System |
Postopek za aktivacijo CD40 in blokada imunske nadzorne točke
|
|
SG11201803678SA
(en)
|
2015-11-03 |
2018-05-30 |
Janssen Biotech Inc |
Subcutaneous formulations of anti-cd38 antibodies and their uses
|
|
EP3370768B9
(en)
|
2015-11-03 |
2022-03-16 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
WO2017079746A2
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
TWI821748B
(zh)
|
2015-11-18 |
2023-11-11 |
美商必治妥施貴寶公司 |
使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
|
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
|
TWI791422B
(zh)
|
2015-11-23 |
2023-02-11 |
美商戊瑞治療有限公司 |
用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
|
|
CA3006934A1
(en)
|
2015-12-01 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof
|
|
KR102809728B1
(ko)
*
|
2015-12-02 |
2025-05-21 |
주식회사 에스티큐브 |
글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법
|
|
HK1250032A1
(zh)
|
2015-12-03 |
2018-11-23 |
Glaxosmithkline Intellectual Property Development Limited |
作为sting调节剂的环状嘌呤二核苷酸
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
AU2016366548C1
(en)
*
|
2015-12-09 |
2024-07-25 |
Bioatla, Llc |
Humanized anti-CD73 antibodies
|
|
BR112018011781A2
(pt)
|
2015-12-14 |
2018-12-04 |
Macrogenics, Inc. |
molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
|
|
US10538497B2
(en)
|
2015-12-15 |
2020-01-21 |
Merck Sharp & Dohme Corp. |
Compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
GB201522311D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
|
US20170174671A1
(en)
|
2015-12-17 |
2017-06-22 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
GB201522309D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
|
WO2017106630A1
(en)
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
US11091556B2
(en)
|
2015-12-18 |
2021-08-17 |
Intervet Inc. |
Caninized human antibodies to human IL-4R alpha
|
|
CN109069623A
(zh)
|
2015-12-18 |
2018-12-21 |
诺华股份有限公司 |
靶向CD32b的抗体及其使用方法
|
|
DK3390451T3
(da)
|
2015-12-18 |
2025-03-17 |
Intervet Int Bv |
Kaniniserede humane antistoffer mod il-4r-alpha hos mennesker og hunde
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
SI3394033T1
(sl)
|
2015-12-22 |
2021-03-31 |
Incyte Corporation |
Heterociklične spojine kot imunomodulatorji
|
|
JP7126941B2
(ja)
|
2015-12-22 |
2022-08-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
がんを治療するための抗pd-1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
|
|
SI3394093T1
(sl)
|
2015-12-23 |
2022-05-31 |
Modernatx, Inc. |
Metode uporabe liganda OX40, ki kodira polinukleotid
|
|
US20200264165A1
(en)
|
2016-01-04 |
2020-08-20 |
Inserm (Institut National De La Sante Et De Larecherche Medicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
|
WO2017120422A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
|
EP3399981B1
(en)
|
2016-01-08 |
2023-08-02 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
BR112018013884A2
(pt)
|
2016-01-08 |
2018-12-18 |
Celgene Corp |
formulações de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
|
|
JP7161938B2
(ja)
|
2016-01-10 |
2022-10-27 |
ネオティーエックス セラピューティクス リミテッド |
スーパー抗原媒介性癌免疫療法の能力を増強するための方法および組成物
|
|
HK1257518A1
(zh)
|
2016-01-11 |
2019-10-25 |
Novartis Ag |
针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
|
|
EP3402503B1
(en)
|
2016-01-13 |
2020-10-21 |
Acerta Pharma B.V. |
Therapeutic combinations of an antifolate and a btk inhibitor
|
|
US10759859B2
(en)
|
2016-01-14 |
2020-09-01 |
Bps Bioscience, Inc. |
Anti-PD-1 antibodies and uses thereof
|
|
CN116327916A
(zh)
|
2016-01-21 |
2023-06-27 |
依奈特制药公司 |
对淋巴细胞中抑制途径的中和
|
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
|
EP3405497A2
(en)
|
2016-01-22 |
2018-11-28 |
Mabquest SA |
Immunological reagents
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
JP6970099B2
(ja)
|
2016-01-28 |
2021-11-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンの処置のための方法及び医薬組成物
|
|
WO2017129769A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for enhancing the potency of the immune checkpoint inhibitors
|
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
DK3411065T3
(da)
|
2016-02-05 |
2021-07-05 |
Orionis Biosciences BV |
Clec9a-bindingsmidler
|
|
KR20180107151A
(ko)
|
2016-02-17 |
2018-10-01 |
노파르티스 아게 |
Tgf베타 2 항체
|
|
AU2017219216B2
(en)
|
2016-02-19 |
2019-12-19 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
WO2017143150A1
(en)
|
2016-02-19 |
2017-08-24 |
City Of Hope |
Bi-specific aptamer
|
|
JP2019513008A
(ja)
|
2016-02-26 |
2019-05-23 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Btlaに対して特異性を有する抗体及びその使用
|
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック, インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
CN109476731A
(zh)
|
2016-02-29 |
2019-03-15 |
基础医药有限公司 |
治疗癌症的方法
|
|
RU2018134771A
(ru)
|
2016-03-04 |
2020-04-06 |
Новартис Аг |
Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение
|
|
US11078274B2
(en)
|
2016-03-08 |
2021-08-03 |
Innate Pharma |
Siglec neutralizing antibodies
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
JP7208492B2
(ja)
|
2016-03-10 |
2023-01-19 |
シージー オンコロジー, インコーポレイテッド |
併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
EP4302782A3
(en)
|
2016-03-15 |
2024-03-27 |
Mersana Therapeutics, Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
|
RU2748378C2
(ru)
|
2016-03-16 |
2021-05-25 |
Амаль Терапьютикс Са |
Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине
|
|
CN110753755B
(zh)
|
2016-03-21 |
2023-12-29 |
丹娜法伯癌症研究院 |
T细胞耗竭状态特异性基因表达调节子及其用途
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
PL3433257T3
(pl)
|
2016-03-24 |
2024-02-12 |
Novartis Ag |
Analogi nukleozydów alkinylu jako inhibitory ludzkiego rinowirusa
|
|
WO2017165778A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
EP3436475A1
(en)
|
2016-03-29 |
2019-02-06 |
STCube & Co., Inc. |
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
|
|
AU2017241440B2
(en)
|
2016-03-29 |
2024-06-27 |
Board Of Regents, The University Of Texas System |
Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
|
|
JP7208010B2
(ja)
|
2016-03-29 |
2023-01-18 |
ユニバーシティ オブ サザン カリフォルニア |
癌を標的とするキメラ抗原受容体
|
|
CN109195990A
(zh)
|
2016-03-30 |
2019-01-11 |
Musc研究发展基金会 |
通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
|
|
EP3225253A1
(en)
|
2016-04-01 |
2017-10-04 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
|
|
WO2017176925A1
(en)
|
2016-04-05 |
2017-10-12 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
|
|
US10975287B2
(en)
|
2016-04-07 |
2021-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
CN109310677A
(zh)
|
2016-04-07 |
2019-02-05 |
凯莫森特里克斯股份有限公司 |
通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
|
|
AU2017247798C1
(en)
|
2016-04-07 |
2020-08-27 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
CN109641037B
(zh)
|
2016-04-13 |
2022-09-06 |
西安奥瑞单抗生物技术有限公司 |
抗psma抗体及其用途
|
|
WO2017178572A1
(en)
|
2016-04-13 |
2017-10-19 |
Vivia Biotech, S.L |
Ex vivo bite-activated t cells
|
|
ES2952680T3
(es)
|
2016-04-28 |
2023-11-03 |
Eisai R&D Man Co Ltd |
Eribulina para inhibir el crecimiento tumoral
|
|
CN109640959B
(zh)
|
2016-04-29 |
2023-03-17 |
西奈山伊坎医学院 |
靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
|
|
JP7131773B2
(ja)
|
2016-04-29 |
2022-09-06 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
ホルモン受容体に関連する転写活性の標的尺度
|
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
AU2017260854B2
(en)
|
2016-05-05 |
2020-01-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of Zeste Homolog 2 inhibitors
|
|
US11753463B2
(en)
|
2016-05-13 |
2023-09-12 |
Orionis Biosciences BV |
Therapeutic targeting of non-cellular structures
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
|
JP7105200B2
(ja)
|
2016-05-13 |
2022-07-22 |
オリオニス バイオサイエンシズ ビーブイ |
標的突然変異体インターフェロン-ベータおよびその使用
|
|
MA45037A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polythérapie à base d'arnm pour le traitement du cancer
|
|
DK3458474T3
(da)
|
2016-05-18 |
2022-09-26 |
Modernatx Inc |
Kombinationer af mrna'er, der koder for immunmodulerende polypeptider og anvendelser deraf
|
|
KR20220159479A
(ko)
|
2016-05-18 |
2022-12-02 |
모더나티엑스, 인크. |
인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
|
|
US11400155B2
(en)
|
2016-05-20 |
2022-08-02 |
Biohaven Therapeutics Ltd. |
Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
CN105968200B
(zh)
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
|
CN109475629A
(zh)
|
2016-05-20 |
2019-03-15 |
伊莱利利公司 |
用notch和pd-1或pd-l1抑制剂的组合治疗
|
|
CN119060177A
(zh)
|
2016-05-20 |
2024-12-03 |
哈普恩治疗公司 |
单结构域血清白蛋白结合蛋白质
|
|
EP3463453A1
(en)
|
2016-05-23 |
2019-04-10 |
Eli Lilly and Company |
Combination of pembrolizumab and abemaciclib for the treatment of cancer
|
|
US20190292259A1
(en)
|
2016-05-24 |
2019-09-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
|
CN106008714B
(zh)
|
2016-05-24 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-1人源化单克隆抗体及其应用
|
|
KR20190032295A
(ko)
|
2016-05-25 |
2019-03-27 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
암 치료 방법 및 조성물
|
|
AU2017271588B2
(en)
|
2016-05-27 |
2022-01-20 |
Agenus Inc. |
Anti-TIM-3 antibodies and methods of use thereof
|
|
CN109789177A
(zh)
|
2016-05-27 |
2019-05-21 |
德那翠丝有限公司 |
腺病毒和免疫调节剂组合治疗
|
|
WO2017210473A1
(en)
|
2016-06-02 |
2017-12-07 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
|
|
EP4248990A3
(en)
|
2016-06-02 |
2024-01-03 |
Bristol-Myers Squibb Company |
Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
|
|
CN109476753A
(zh)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
用于治疗肿瘤的方法的抗-pd-1抗体
|
|
CN109476754A
(zh)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
抗-pd-1抗体在治疗结肠直肠癌患者中的用途
|
|
JP2019517507A
(ja)
|
2016-06-03 |
2019-06-24 |
イムクローン リミテッド ライアビリティ カンパニー |
特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
|
|
EP4386005A3
(en)
|
2016-06-03 |
2024-09-04 |
Bristol-Myers Squibb Company |
Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
EP3468960B1
(en)
|
2016-06-08 |
2022-03-23 |
GlaxoSmithKline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
US10851053B2
(en)
|
2016-06-08 |
2020-12-01 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
CN108350082B
(zh)
*
|
2016-06-13 |
2021-09-24 |
天境生物科技(上海)有限公司 |
Pd-l1抗体及其用途
|
|
MX2018015592A
(es)
*
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
|
PH12018502523B1
(en)
|
2016-06-14 |
2023-05-12 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
EP3471754A1
(en)
|
2016-06-20 |
2019-04-24 |
Kymab Limited |
Anti-pd-l1 antibodies
|
|
ES2927984T3
(es)
|
2016-06-20 |
2022-11-14 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
MX391135B
(es)
|
2016-06-24 |
2025-03-21 |
Infinity Pharmaceuticals Inc |
Terapias de combinacion.
|
|
WO2018002181A1
(en)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
RU2656181C1
(ru)
*
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
CN116769050A
(zh)
|
2016-07-20 |
2023-09-19 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
|
US20190241573A1
(en)
|
2016-07-20 |
2019-08-08 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
|
US11746152B2
(en)
|
2016-07-20 |
2023-09-05 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
|
|
CA3032054A1
(en)
*
|
2016-07-28 |
2018-02-01 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and pd-1 inhibitors
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
JP2019525934A
(ja)
|
2016-07-29 |
2019-09-12 |
イーライ リリー アンド カンパニー |
癌の治療に使用するためのメレスチニブおよび抗pd−l1または抗pd−1阻害剤を用いた組み合わせ治療
|
|
US20210369746A1
(en)
|
2016-08-01 |
2021-12-02 |
Molecular Templates, Inc. |
Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
AU2017305366B2
(en)
*
|
2016-08-04 |
2019-06-20 |
Innovent Biologics (Suzhou) Co., Ltd |
Anti-PD-L1 nanobody and use thereof
|
|
US11248048B2
(en)
|
2016-08-05 |
2022-02-15 |
Y-Biologics Inc. |
Antibody to programmed cell death 1 (PD-1) and use thereof
|
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
|
PT3500299T
(pt)
|
2016-08-19 |
2024-02-21 |
Beigene Switzerland Gmbh |
Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
|
|
JP7045378B2
(ja)
|
2016-09-01 |
2022-03-31 |
キメラ・バイオエンジニアリング,インコーポレーテッド |
Gold最適化CAR T細胞
|
|
WO2018049015A1
(en)
|
2016-09-07 |
2018-03-15 |
Trustees Of Tufts College |
Combination therapies using immuno-dash inhibitors and pd-1 antagonists
|
|
JP2019526595A
(ja)
|
2016-09-09 |
2019-09-19 |
ティージー セラピューティクス,インコーポレイテッド |
血液癌を治療するための抗cd20抗体、pi3キナーゼ−デルタ阻害剤および抗pd−1抗体または抗pd−l1抗体の組み合わせ
|
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
WO2018046736A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
WO2018046738A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
RU2752562C2
(ru)
|
2016-09-14 |
2021-07-29 |
Эббви Байотерапьютикс Инк. |
Антитела к pd-1(cd279)
|
|
JP7164528B2
(ja)
*
|
2016-09-14 |
2022-11-01 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド |
Pd-1に特異的に結合する可能な抗体及びその機能的断片
|
|
KR102257154B1
(ko)
|
2016-09-19 |
2021-05-28 |
셀진 코포레이션 |
Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
|
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
|
JP7346291B2
(ja)
|
2016-09-21 |
2023-09-19 |
アマル セラピューティクス エスエー |
癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びtlrペプチドアゴニストを含む融合体
|
|
AU2017332161B9
(en)
|
2016-09-21 |
2024-08-22 |
The United States Government As Represented By The Department Of Veterans Affairs |
Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
|
|
WO2018055080A1
(en)
|
2016-09-22 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
|
|
JP7274413B2
(ja)
|
2016-09-23 |
2023-05-16 |
マレンゴ・セラピューティクス,インコーポレーテッド |
ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
|
|
EP3515940A1
(en)
|
2016-09-26 |
2019-07-31 |
ImClone LLC |
Combination therapy for cancer
|
|
WO2018064165A2
(en)
|
2016-09-27 |
2018-04-05 |
Board Of Regents, The University Of Texas System |
Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
|
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
|
JP7424727B2
(ja)
|
2016-09-29 |
2024-01-30 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド |
ヘテロダイマー免疫グロブリン構造体及びその製造方法
|
|
CR20190168A
(es)
|
2016-10-04 |
2019-05-17 |
Merck Sharp & Dohme |
Compuestos de benzo[b]tiofeno como agonistas de sting
|
|
IL265759B2
(en)
|
2016-10-06 |
2025-10-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
IL265762B2
(en)
|
2016-10-06 |
2024-04-01 |
Merck Patent Gmbh |
Dosing regimen of avelumab for the treatment of cancer
|
|
JP7116278B2
(ja)
|
2016-10-07 |
2022-08-10 |
エンテローム エスエー |
癌治療のための免疫原性化合物
|
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
CN110022894B
(zh)
|
2016-10-07 |
2024-01-19 |
恩特罗姆公司 |
用于癌症疗法的免疫原性化合物
|
|
EP3522917A2
(en)
|
2016-10-07 |
2019-08-14 |
Enterome S.A. |
Microbiota sequence variants of tumor-related antigenic epitopes
|
|
WO2018068201A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
RU2759728C2
(ru)
|
2016-10-11 |
2021-11-17 |
Ситлимик Инк. |
Лекарственное средство
|
|
BR112019007369A2
(pt)
|
2016-10-11 |
2019-07-16 |
Agenus Inc |
anticorpos anti-lag-3 e métodos de uso dos mesmos
|
|
KR102661905B1
(ko)
|
2016-10-12 |
2024-04-29 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Tusc2 면역요법을 위한 방법 및 조성물
|
|
BR112019007145A2
(pt)
*
|
2016-10-14 |
2019-07-02 |
Eisai R&D Man Co Ltd |
combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial
|
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
|
US10597454B2
(en)
*
|
2016-10-15 |
2020-03-24 |
Innovent Biologics (Suzhou) Co., Ltd |
PD-1 antibodies
|
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
|
WO2018075447A1
(en)
|
2016-10-19 |
2018-04-26 |
The Trustees Of Columbia University In The City Of New York |
Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
|
|
CA3040802A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
|
KR102634093B1
(ko)
|
2016-10-28 |
2024-02-07 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
CN110062885A
(zh)
|
2016-11-01 |
2019-07-26 |
安奈普泰斯生物有限公司 |
针对t细胞免疫球蛋白和粘蛋白3(tim-3)的抗体
|
|
KR20190101364A
(ko)
|
2016-11-01 |
2019-08-30 |
테사로, 인코포레이티드 |
예정 사멸-1(pd-1)에 대한 항체
|
|
MX2019004834A
(es)
|
2016-11-02 |
2019-06-20 |
Jounce Therapeutics Inc |
Anticuerpos de pd-1 y usos de estos.
|
|
WO2018083087A2
(en)
|
2016-11-02 |
2018-05-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Binding proteins
|
|
AU2017353427A1
(en)
|
2016-11-02 |
2019-05-16 |
Bristol-Myers Squibb Company |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
BR112019008223A2
(pt)
|
2016-11-03 |
2019-07-16 |
Bristol-Myers Squibb Company |
anticorpos anti-ctla-4 ativáveis e usos dos mesmos
|
|
US10342785B2
(en)
|
2016-11-04 |
2019-07-09 |
Askat Inc. |
Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
|
|
CN118480125A
(zh)
*
|
2016-11-08 |
2024-08-13 |
齐鲁皮吉特湾生物治疗有限公司 |
抗pd1和抗ctla4抗体
|
|
CN110520534A
(zh)
*
|
2016-11-09 |
2019-11-29 |
恩根尼公司 |
程序性死亡配体1的肠表达
|
|
CA3043356A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
WO2018087391A1
(en)
|
2016-11-14 |
2018-05-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
|
CN117599061A
(zh)
|
2016-11-17 |
2024-02-27 |
得克萨斯州大学系统董事会 |
具有针对携带egfr或her2外显子20突变之癌细胞的抗肿瘤活性的化合物
|
|
WO2018091661A1
(en)
*
|
2016-11-18 |
2018-05-24 |
Symphogen A/S |
Anti-pd-1 antibodies and compositions
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
EA201990894A9
(ru)
*
|
2016-11-18 |
2019-11-27 |
|
Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
|
|
WO2018091542A1
(en)
|
2016-11-21 |
2018-05-24 |
Idenix Pharmaceuticals Llc |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
|
WO2018101448A1
(en)
|
2016-11-30 |
2018-06-07 |
Kyowa Hakko Kirin Co., Ltd. |
Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
|
|
CA3045241A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
CN110234342A
(zh)
|
2016-12-01 |
2019-09-13 |
葛兰素史密斯克莱知识产权发展有限公司 |
组合疗法
|
|
KR20190104529A
(ko)
|
2016-12-03 |
2019-09-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Car-t 세포의 조절 방법
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
PT3551660T
(pt)
|
2016-12-07 |
2023-11-30 |
Ludwig Inst For Cancer Res Ltd |
Anticorpos anti-ctla-4 e métodos de uso dos mesmos
|
|
KR102603681B1
(ko)
|
2016-12-07 |
2023-11-17 |
아게누스 인코포레이티드 |
항체 및 이의 사용방법
|
|
CN110234647B
(zh)
|
2016-12-08 |
2023-05-23 |
利克斯特生物技术公司 |
用于调节免疫应答的氧杂双环庚烷
|
|
TW202508642A
(zh)
|
2016-12-12 |
2025-03-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
|
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
CN106519034B
(zh)
|
2016-12-22 |
2020-09-18 |
鲁南制药集团股份有限公司 |
抗pd-1抗体及其用途
|
|
EP3558963B1
(en)
|
2016-12-22 |
2022-03-23 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
MX391981B
(es)
|
2016-12-22 |
2025-03-21 |
Incyte Corp |
Derivados de benzooxazol como inmunomoduladores.
|
|
US11248049B2
(en)
|
2016-12-23 |
2022-02-15 |
Remd Biotherapeutics, Inc. |
Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
|
|
WO2018115458A1
(en)
|
2016-12-23 |
2018-06-28 |
Virttu Biologics Limited |
Treatment of cancer
|
|
CN107043420B
(zh)
*
|
2016-12-26 |
2018-07-31 |
中国科学院微生物研究所 |
一种抗pd-1抗体及其应用
|
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
|
MX2019008207A
(es)
|
2017-01-09 |
2019-12-11 |
Tesaro Inc |
Métodos para tratar el cáncer con anticuerpos anti-pd-1.
|
|
MA47206A
(fr)
|
2017-01-09 |
2019-11-13 |
Tesaro Inc |
Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
|
|
EP3565549B1
(en)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
WO2018132427A1
(en)
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
Targeted t cells with cytotoxicity toward immunosuppressive cells
|
|
MA47265A
(fr)
|
2017-01-13 |
2019-11-20 |
Agenus Inc |
Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
US20200237874A1
(en)
|
2017-01-20 |
2020-07-30 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
BR112019013238A2
(pt)
*
|
2017-01-20 |
2020-02-11 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anticorpos anti-pd-1 e usos dos mesmos
|
|
CN108341871A
(zh)
|
2017-01-24 |
2018-07-31 |
三生国健药业(上海)股份有限公司 |
抗pd-1单克隆抗体及其制备方法和应用
|
|
CN110461847B
(zh)
|
2017-01-25 |
2022-06-07 |
百济神州有限公司 |
(S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
|
|
US10434095B2
(en)
|
2017-01-27 |
2019-10-08 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
AU2018216032B2
(en)
|
2017-02-06 |
2022-04-07 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
|
CN110573172A
(zh)
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
WO2018146148A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for predicting the response to checkpoint blockade cancer immunotherapy
|
|
WO2018146128A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
JP7161481B2
(ja)
|
2017-02-10 |
2022-10-26 |
ノバルティス アーゲー |
1-(4-アミノ-5-ブロモ-6-(1h-ピラゾール-1-イル)ピリミジン-2-イル)-1h-ピラゾール-4-オール及びがんの治療におけるその使用
|
|
EP3582855A1
(en)
|
2017-02-15 |
2019-12-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
JP7324710B2
(ja)
|
2017-02-21 |
2023-08-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
肺癌の処置のための抗pd-1抗体
|
|
CN110325209A
(zh)
|
2017-02-24 |
2019-10-11 |
宏观基因有限公司 |
能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
|
|
CN110612447B
(zh)
|
2017-02-24 |
2024-02-06 |
德克萨斯州立大学董事会 |
用于检测早期胰腺癌的测定
|
|
EP3585437B1
(en)
|
2017-02-24 |
2022-12-21 |
Bayer Pharma Aktiengesellschaft |
Combinations of copanlisib with anti-pd-1 antibody
|
|
EP3585486A1
(en)
|
2017-02-27 |
2020-01-01 |
Novartis AG |
Dosing schedule for a combination of ceritinib and an anti-pd-1 antibody molecule
|
|
EP3585782A1
(en)
|
2017-02-27 |
2020-01-01 |
GlaxoSmithKline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
|
UY37621A
(es)
|
2017-02-28 |
2018-09-28 |
Sanofi Sa |
Arn terapéutico que codifica citoquinas
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
US20200150125A1
(en)
|
2017-03-12 |
2020-05-14 |
Yeda Research And Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
AU2018235944B2
(en)
|
2017-03-15 |
2024-01-04 |
Amgen Inc. |
Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
|
|
EP3600427A1
(en)
|
2017-03-24 |
2020-02-05 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
WO2018183459A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Celgene Corporation |
Formulations comprising pd-1 binding proteins and methods of making thereof
|
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
|
KR20190130644A
(ko)
|
2017-03-31 |
2019-11-22 |
베링거 인겔하임 인터내셔날 게엠베하 |
항암 조합 요법
|
|
SG10202110594UA
(en)
|
2017-03-31 |
2021-11-29 |
Bristol Myers Squibb Co |
Methods of treating tumor
|
|
WO2018183408A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody
|
|
EP3601353A1
(en)
|
2017-03-31 |
2020-02-05 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
CN117003887A
(zh)
|
2017-04-03 |
2023-11-07 |
豪夫迈·罗氏有限公司 |
抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
|
|
EP3606960A1
(en)
|
2017-04-03 |
2020-02-12 |
Oncologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
EP3606957A1
(en)
|
2017-04-05 |
2020-02-12 |
Symphogen A/S |
Combination therapies targeting pd-1, tim-3, and lag-3
|
|
US11285207B2
(en)
|
2017-04-05 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specifically binding to PD1 and LAG3
|
|
CN110505884B
(zh)
|
2017-04-05 |
2022-08-12 |
勃林格殷格翰国际有限公司 |
抗癌组合疗法
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
IL270021B
(en)
|
2017-04-18 |
2022-08-01 |
Tempest Therapeutics Inc |
Bicyclic compounds and their use in the treatment of cancer
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
CA3058944A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
CN106939049B
(zh)
*
|
2017-04-20 |
2019-10-01 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
|
|
CA3060516A1
(en)
|
2017-04-21 |
2018-10-25 |
Sillajen, Inc. |
Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
MX2019012849A
(es)
|
2017-04-28 |
2019-11-28 |
Five Prime Therapeutics Inc |
Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
TW201900193A
(zh)
|
2017-04-28 |
2019-01-01 |
美商默沙東藥廠 |
用於癌症治療之生物標記物
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
US20200385472A1
(en)
|
2017-04-28 |
2020-12-10 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP4275698A3
(en)
|
2017-05-01 |
2024-05-15 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
MX2019013072A
(es)
*
|
2017-05-02 |
2019-12-16 |
Merck Sharp & Dohme |
Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
|
|
UY37718A
(es)
|
2017-05-05 |
2018-11-30 |
Novartis Ag |
2-quinolinonas triciclicas como agentes antibacteriales
|
|
MX2019013373A
(es)
|
2017-05-09 |
2020-08-03 |
Tesaro Inc |
Terapias de combinación para tratar cáncer.
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
EP3621624B1
(en)
|
2017-05-12 |
2023-08-30 |
Merck Sharp & Dohme LLC |
Cyclic di-nucleotide compounds as sting agonists
|
|
CA3063893A1
(en)
*
|
2017-05-16 |
2018-11-22 |
Immunogen, Inc. |
Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations
|
|
WO2018213297A1
(en)
|
2017-05-16 |
2018-11-22 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-gitr agonist antibodies
|
|
JP2020520923A
(ja)
|
2017-05-17 |
2020-07-16 |
ボストン バイオメディカル, インコーポレイテッド |
がんを処置するための方法
|
|
EP3625246A1
(en)
|
2017-05-18 |
2020-03-25 |
ModernaTX, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
|
MA49144A
(fr)
|
2017-05-18 |
2020-03-25 |
Tesaro Inc |
Polythérapies pour le traitement du cancer
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
EA201992765A1
(ru)
|
2017-05-24 |
2020-03-25 |
Новартис Аг |
Белки на основе антител с привитым цитокином и способы их применения в лечении рака
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
BR112019025352A8
(pt)
|
2017-05-29 |
2022-12-13 |
Gamamabs Pharma |
Inibidor de imunossupressão associada ao câncer
|
|
WO2018222711A2
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
SMT202300418T1
(it)
|
2017-05-30 |
2024-01-10 |
Bristol Myers Squibb Co |
Trattamento di tumori positivi per lag-3
|
|
WO2018222722A2
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
|
JP2020522254A
(ja)
|
2017-05-31 |
2020-07-30 |
エルスター セラピューティクス, インコーポレイテッド |
骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用
|
|
JP7768666B2
(ja)
|
2017-05-31 |
2025-11-12 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
|
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
|
CN110678483B
(zh)
|
2017-06-01 |
2023-09-22 |
百时美施贵宝公司 |
用抗pd-1抗体治疗肿瘤的方法
|
|
US20200181274A1
(en)
|
2017-06-01 |
2020-06-11 |
Novartis Ag |
Bispecific antibodies that bind cd 123 cd3
|
|
WO2018223101A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
BR112019022074A2
(pt)
|
2017-06-02 |
2020-05-12 |
Boehringer Ingelheim International Gmbh |
Terapia de combinação anticâncer
|
|
EP3630126A4
(en)
|
2017-06-02 |
2021-03-17 |
The Penn State Research Foundation |
CERAMIDE NANOLIPOSOMES, COMPOSITIONS AND METHODS OF USE FOR IMMUNOTHERAPY
|
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
CN110869049A
(zh)
|
2017-06-09 |
2020-03-06 |
葛兰素史克知识产权开发有限公司 |
组合疗法
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
EP4461825A3
(en)
|
2017-06-09 |
2024-11-20 |
Providence Health & Services - Oregon |
Tumor-infiltrating t-cells for use in the treatment of cancer
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
CN107083398A
(zh)
*
|
2017-06-16 |
2017-08-22 |
深圳惠升生物科技有限公司 |
植物作为宿主在表达pd‑1抗体和/或pd‑l1抗体中的应用
|
|
EP3641739A1
(en)
|
2017-06-20 |
2020-04-29 |
Institut Curie |
Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
|
|
BR112019027402A2
(pt)
|
2017-06-22 |
2020-07-07 |
Celgene Corporation |
tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
|
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN110799537B
(zh)
*
|
2017-06-25 |
2023-07-28 |
西雅图免疫公司 |
抗pd-1抗体及其制备和使用方法
|
|
TWI877099B
(zh)
|
2017-06-26 |
2025-03-21 |
英屬開曼群島商百濟神州有限公司 |
抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
|
|
JP2020525483A
(ja)
|
2017-06-27 |
2020-08-27 |
ノバルティス アーゲー |
抗tim−3抗体のための投与レジメンおよびその使用
|
|
CN111050545A
(zh)
|
2017-06-29 |
2020-04-21 |
朱诺治疗学股份有限公司 |
评估与免疫疗法相关的毒性的小鼠模型
|
|
SG11201913008TA
(en)
|
2017-06-30 |
2020-01-30 |
Celgene Corp |
Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-doxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
|
|
EP3649108A1
(en)
|
2017-07-03 |
2020-05-13 |
GlaxoSmithKline Intellectual Property Development Limited |
2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
JP2020525513A
(ja)
|
2017-07-03 |
2020-08-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌および他の疾患を治療するためのatf4阻害剤としてのn−(3−(2−(4−クロロフェノキシ)アセトアミドビシクロ[1.1.1]ペンタン−1−イル)−2−シクロブタン−1−カルボキサミド誘導体および関連化合物
|
|
AU2018301335B2
(en)
|
2017-07-10 |
2022-09-15 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
US11623954B2
(en)
|
2017-07-10 |
2023-04-11 |
Innate Pharma |
Siglec-9-neutralizing antibodies
|
|
KR102698385B1
(ko)
|
2017-07-14 |
2024-08-22 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
|
EP3655542A1
(en)
|
2017-07-18 |
2020-05-27 |
Institut Gustave Roussy |
Method for assessing the response to pd-1/pdl-1 targeting drugs
|
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗lag−3抗体の投薬量レジメンおよびその使用
|
|
JP7760242B2
(ja)
|
2017-07-21 |
2025-10-27 |
ジェネンテック, インコーポレイテッド |
がんの治療法及び診断法
|
|
WO2019020593A1
(en)
|
2017-07-25 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
CN111148996A
(zh)
|
2017-07-28 |
2020-05-12 |
百时美施贵宝公司 |
用于检查点抑制剂的预测性外周血生物标志物
|
|
EP3661498A4
(en)
|
2017-08-04 |
2021-04-21 |
Merck Sharp & Dohme Corp. |
BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
|
|
WO2019027857A1
(en)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
|
|
TWI785098B
(zh)
|
2017-08-18 |
2022-12-01 |
開曼群島商科賽睿生命科學公司 |
Tg02之多晶型
|
|
MX2020001980A
(es)
|
2017-08-28 |
2020-03-24 |
Bristol Myers Squibb Co |
Antagonistas de celulas t con dominios de inmunoglobulina y mucina 3 (tim-3) para el tratamiento y diagnostico de canceres.
|
|
KR20200052327A
(ko)
|
2017-09-04 |
2020-05-14 |
아게누스 인코포레이티드 |
혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
|
|
TW201922721A
(zh)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
化學化合物
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
|
WO2019057744A1
(en)
|
2017-09-19 |
2019-03-28 |
Institut Curie |
AROMATIC HYDROCARBON RECEPTOR AGONIST FOR USE IN ASSOCIATION TREATMENT AGAINST CANCER
|
|
CN111712242B
(zh)
|
2017-09-25 |
2023-11-24 |
凯莫森特里克斯股份有限公司 |
使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
JP2020535180A
(ja)
|
2017-09-29 |
2020-12-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗igf、抗pf−1の抗がん組み合わせ治療
|
|
EP3691643A4
(en)
|
2017-09-29 |
2021-06-16 |
Bristol-Myers Squibb Company |
COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
|
|
WO2019067978A1
(en)
|
2017-09-30 |
2019-04-04 |
Tesaro, Inc. |
POLYTHERAPIES FOR THE TREATMENT OF CANCER
|
|
WO2019070497A1
(en)
|
2017-10-04 |
2019-04-11 |
Imclone Llc |
POLY THERAPY AGAINST CANCER
|
|
US20210238172A1
(en)
|
2017-10-05 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators and methods of using the same
|
|
US11377440B2
(en)
|
2017-10-05 |
2022-07-05 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING)
|
|
RU2020115161A
(ru)
*
|
2017-10-06 |
2021-11-08 |
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи |
Днк моноклональных антител против ctla-4 для лечения и профилактики рака
|
|
EP3691685A1
(en)
|
2017-10-06 |
2020-08-12 |
Tesaro Inc. |
Combination therapies and uses thereof
|
|
AU2018348432B2
(en)
|
2017-10-09 |
2025-08-28 |
Enterome S.A. |
Microbiota sequence variants of tumor-related antigenic epitopes
|
|
CN111194308A
(zh)
|
2017-10-11 |
2020-05-22 |
奥瑞基尼探索技术有限公司 |
3-取代的1,2,4-噁二唑的结晶形式
|
|
CN119930795A
(zh)
|
2017-10-12 |
2025-05-06 |
得克萨斯大学体系董事会 |
用于免疫疗法的t细胞受体
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CN111212646A
(zh)
|
2017-10-13 |
2020-05-29 |
美国默沙东药厂 |
用于治疗弥漫性大b细胞淋巴瘤的组合物和方法
|
|
BR112020007196A2
(pt)
|
2017-10-13 |
2020-12-01 |
Harpoon Therapeutics, Inc. |
proteínas triespecíficas e métodos de uso
|
|
CN111247169A
(zh)
|
2017-10-15 |
2020-06-05 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
EP3697434A1
(en)
|
2017-10-18 |
2020-08-26 |
Vivia Biotech, S.L. |
Bite-activated car-t cells
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
EP3700544A1
(en)
|
2017-10-27 |
2020-09-02 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating liver cancer
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
JP2021502961A
(ja)
|
2017-10-31 |
2021-02-04 |
ヤンセン バイオテツク,インコーポレーテツド |
高リスク多発性骨髄腫の治療方法
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
EP3703692B1
(en)
|
2017-11-01 |
2025-07-23 |
Merck Sharp & Dohme LLC |
Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
JP7447006B2
(ja)
|
2017-11-01 |
2024-03-11 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞成熟抗原(bcma)に特異的なキメラ抗原受容体
|
|
CN111511370A
(zh)
|
2017-11-01 |
2020-08-07 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
|
|
WO2019087087A1
(en)
|
2017-11-03 |
2019-05-09 |
Aurigene Discovery Technologies Limited |
Dual inhibitors of tim-3 and pd-1 pathways
|
|
EA202090749A1
(ru)
|
2017-11-06 |
2020-08-19 |
Ориджен Дискавери Текнолоджис Лимитед |
Способы совместной терапии для иммуномодуляции
|
|
AU2018360790A1
(en)
|
2017-11-06 |
2020-06-11 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
CN111601823B
(zh)
|
2017-11-07 |
2024-09-24 |
德克萨斯大学体系董事会 |
用car-t或car-nk细胞在癌症治疗中靶向lilrb4
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗pd−1配列を用いた二重特異性および単一特異性抗体
|
|
KR102718287B1
(ko)
|
2017-11-14 |
2024-10-16 |
머크 샤프 앤드 돔 엘엘씨 |
인돌아민 2,3-디옥시게나제 (ido) 억제제로서의 신규 치환된 비아릴 화합물
|
|
US11498904B2
(en)
|
2017-11-14 |
2022-11-15 |
Merck Sharp & Dohme Llc |
Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
|
|
WO2019099838A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
BR112020009759A8
(pt)
|
2017-11-17 |
2023-01-31 |
Merck Sharp & Dohme |
Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos
|
|
JP2021503458A
(ja)
|
2017-11-17 |
2021-02-12 |
ノバルティス アーゲー |
新規のジヒドロイソキサゾール化合物及びb型肝炎治療のためのそれらの使用
|
|
CN111670043A
(zh)
|
2017-11-24 |
2020-09-15 |
国家医疗保健研究所 |
治疗癌症的方法和组合物
|
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
TW201925782A
(zh)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
靶向bcma之嵌合抗原受體及其用途
|
|
EP3720881A1
(en)
|
2017-12-08 |
2020-10-14 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
US20200345648A1
(en)
|
2017-12-15 |
2020-11-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treating cancer using exosomes-associated gene editing
|
|
EP3724225A1
(en)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
JP2021507906A
(ja)
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
WO2019126691A1
(en)
|
2017-12-21 |
2019-06-27 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
BR112020013285A2
(pt)
|
2017-12-28 |
2020-12-01 |
The General Hospital Corporation |
direcionamento do complexo de sinalossoma cbm que induz células t reguladoras a atingirem o microambiente tumoral
|
|
CN111699198B
(zh)
|
2017-12-28 |
2023-09-05 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
|
WO2019134946A1
(en)
|
2018-01-04 |
2019-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
|
AU2019205784B2
(en)
|
2018-01-08 |
2024-07-25 |
Chemocentryx, Inc. |
Methods of treating solid tumors with CCR2 antagonists
|
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
EP3737376B1
(en)
|
2018-01-09 |
2024-04-17 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human diseases
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
JP2021510733A
(ja)
|
2018-01-12 |
2021-04-30 |
ケーディーエーシー セラピューティクス,インコーポレーテッドKdac Therapeutics, Inc. |
がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ
|
|
SG11202005323SA
(en)
|
2018-01-12 |
2020-07-29 |
Bristol Myers Squibb Co |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
|
JP2021511372A
(ja)
|
2018-01-16 |
2021-05-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Tim3に対する抗体で癌を処置する方法
|
|
US20210038559A1
(en)
|
2018-01-22 |
2021-02-11 |
Thomas Richard Gadek |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
|
EA202091751A1
(ru)
|
2018-01-22 |
2020-11-06 |
Бристол-Маерс Сквибб Компани |
Композиции и способы лечения рака
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
US20200354424A1
(en)
|
2018-01-26 |
2020-11-12 |
Orionis Biosciences, Inc. |
Xcr1 binding agents and uses thereof
|
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
KR20200128014A
(ko)
|
2018-01-31 |
2020-11-11 |
셀진 코포레이션 |
입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
|
|
AU2019215031B2
(en)
|
2018-01-31 |
2025-10-09 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
WO2019148410A1
(en)
*
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
WO2019148412A1
(en)
*
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
WO2019149286A1
(en)
|
2018-02-05 |
2019-08-08 |
Shenzhen Ionova Life Science Co., Ltd. |
Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
|
|
US11896643B2
(en)
|
2018-02-05 |
2024-02-13 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
WO2019157124A1
(en)
|
2018-02-08 |
2019-08-15 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
|
NL2020422B1
(en)
|
2018-02-12 |
2019-08-19 |
Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis |
Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy.
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3752193A4
(en)
*
|
2018-02-13 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES
|
|
EP3752180A4
(en)
|
2018-02-13 |
2021-12-15 |
Merck Sharp & Dohme Corp. |
METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES
|
|
WO2019162325A1
(en)
|
2018-02-21 |
2019-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
|
CN111741978A
(zh)
|
2018-02-21 |
2020-10-02 |
戊瑞治疗有限公司 |
B7-h4抗体制剂
|
|
US12090142B2
(en)
|
2018-02-22 |
2024-09-17 |
Board Of Regents, The University Of Texas System |
Combination therapy for the treatment of cancer
|
|
IL276675B2
(en)
|
2018-02-23 |
2023-10-01 |
Eucure Beijing Biopharma Co Ltd |
Anti-PD-1 antibodies and uses thereof
|
|
AU2019227607C1
(en)
|
2018-02-27 |
2023-07-20 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
|
|
JP2021514982A
(ja)
|
2018-02-28 |
2021-06-17 |
ノバルティス アーゲー |
インドール−2−カルボニル化合物及びb型肝炎治療のためのそれらの使用
|
|
CN111867679A
(zh)
|
2018-03-06 |
2020-10-30 |
居里研究所 |
用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂
|
|
IL277095B2
(en)
|
2018-03-07 |
2025-10-01 |
Pfizer |
Preparations containing anti-PD-1 antibody
|
|
GB201803745D0
(en)
*
|
2018-03-08 |
2018-04-25 |
Ultrahuman Eight Ltd |
PD1 binding agents
|
|
EP3765006A4
(en)
|
2018-03-13 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
ARGINASE INHIBITORS AND METHODS OF USE
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CA3092635A1
(en)
|
2018-03-14 |
2019-09-19 |
Surface Oncology, Inc. |
Antibodies that bind cd39 and uses thereof
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
AU2019322487B2
(en)
|
2018-03-19 |
2024-04-18 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法
|
|
MA52094A
(fr)
|
2018-03-22 |
2021-01-27 |
Adimab Llc |
Anticorps anti-il-27 et leurs utilisations
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
Micaおよび/またはmicbに対する抗体ならびにそれらの使用
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
BR112020019418A2
(pt)
|
2018-03-25 |
2021-02-17 |
Snipr Biome Aps. |
tratamento e prevenção de infecções microbianas
|
|
EP3773551B1
(en)
|
2018-03-27 |
2024-10-16 |
Board of Regents, The University of Texas System |
Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
|
|
CN108530537B
(zh)
*
|
2018-03-29 |
2019-07-02 |
中国人民解放军军事科学院军事医学研究院 |
Pd-1/pd-l1信号通路抑制剂
|
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
JP2021519771A
(ja)
|
2018-03-30 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍を処置する方法
|
|
SMT202300065T1
(it)
|
2018-03-30 |
2023-05-12 |
Incyte Corp |
Composti eterociclici come immunomodulatori
|
|
EP3774765A4
(en)
|
2018-04-03 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
|
US10793557B2
(en)
|
2018-04-03 |
2020-10-06 |
Merck Sharp & Dohme Corp. |
Sting agonist compounds
|
|
CN112292399A
(zh)
|
2018-04-04 |
2021-01-29 |
百时美施贵宝公司 |
抗cd27抗体及其用途
|
|
WO2019195658A1
(en)
|
2018-04-05 |
2019-10-10 |
Dana-Farber Cancer Institute, Inc. |
Sting levels as a biomarker for cancer immunotherapy
|
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
|
EP3773714A1
(en)
|
2018-04-12 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
WO2019200214A1
(en)
|
2018-04-13 |
2019-10-17 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cancer
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
DK3781550T3
(da)
|
2018-04-17 |
2025-01-27 |
Tempest Therapeutics Inc |
Bicykliske carboxamider og fremgangsmåder til anvendelse deraf
|
|
CA3097625A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
CN119286871A
(zh)
|
2018-04-19 |
2025-01-10 |
查美特制药公司 |
合成rig-i样受体激动剂
|
|
WO2019204179A1
(en)
|
2018-04-20 |
2019-10-24 |
Merck Sharp & Dohme Corp. |
Novel substituted rig-i agonists: compositions and methods thereof
|
|
PE20210160A1
(es)
|
2018-04-25 |
2021-01-26 |
Innate Tumor Immunity Inc |
Moduladores de nlrp3
|
|
TW202012430A
(zh)
|
2018-04-26 |
2020-04-01 |
美商艾吉納斯公司 |
熱休克蛋白質-結合之胜肽組成物及其使用方法
|
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
JP6630026B1
(ja)
*
|
2018-04-27 |
2020-01-15 |
隆代 大田 |
免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー
|
|
CN108840932B
(zh)
*
|
2018-04-28 |
2022-03-29 |
中国科学院微生物研究所 |
一种pd-1特异性抗体及其抗肿瘤应用
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
KR20210006405A
(ko)
|
2018-05-04 |
2021-01-18 |
메르크 파텐트 게엠베하 |
암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
|
|
CN119241541A
(zh)
|
2018-05-04 |
2025-01-03 |
因赛特公司 |
Fgfr抑制剂的固体形式和其制备方法
|
|
PE20210919A1
(es)
|
2018-05-04 |
2021-05-19 |
Incyte Corp |
Sales de un inhibidor de fgfr
|
|
IL278522B2
(en)
|
2018-05-07 |
2025-10-01 |
Genmab As |
Methods for treating cancer with a combination of anti-PD-1 antibody and always an anti-tissue factor antibody drug
|
|
PL3790877T3
(pl)
|
2018-05-11 |
2023-06-12 |
Incyte Corporation |
Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
|
|
US12209126B2
(en)
|
2018-05-15 |
2025-01-28 |
Medimmune Limited |
Treatment of cancer
|
|
WO2019222359A1
(en)
|
2018-05-15 |
2019-11-21 |
Duke University |
Systems and methods for genetic manipulation of akkermansia species
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
TWI806870B
(zh)
*
|
2018-05-23 |
2023-07-01 |
中國大陸商大有華夏生物醫藥集團有限公司 |
抗pd-1抗體及其用途
|
|
CN112399848B
(zh)
|
2018-05-23 |
2024-09-06 |
细胞基因公司 |
用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体
|
|
JP7495886B2
(ja)
|
2018-05-23 |
2024-06-05 |
セルジーン コーポレイション |
多発性骨髄腫を治療すること及び4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルのバイオマーカーの使用
|
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
WO2019224385A2
(en)
*
|
2018-05-24 |
2019-11-28 |
Glenmark Pharmaceuticals S.A. |
Combined bispecific antibody and immuno-oncology therapies
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US11932681B2
(en)
|
2018-05-31 |
2024-03-19 |
Novartis Ag |
Hepatitis B antibodies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
EP3810109B1
(en)
|
2018-05-31 |
2024-08-07 |
Peloton Therapeutics, Inc. |
Compounds and compositions for inhibiting cd73
|
|
WO2019230919A1
(ja)
|
2018-05-31 |
2019-12-05 |
小野薬品工業株式会社 |
免疫チェックポイント阻害薬の有効性判定バイオマーカー
|
|
WO2019231870A1
(en)
|
2018-05-31 |
2019-12-05 |
Merck Sharp & Dohme Corp. |
Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
IL317554A
(en)
|
2018-06-01 |
2025-02-01 |
Novartis Ag |
Anti-BCMA binding molecules and their uses
|
|
CA3102256A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
|
US11555071B2
(en)
|
2018-06-03 |
2023-01-17 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against CEACAM5 and CD47
|
|
CA3103610A1
(en)
|
2018-06-12 |
2019-12-19 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
CN112203725A
(zh)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
Bcma嵌合抗原受体及其用途
|
|
CA3103629A1
(en)
|
2018-06-15 |
2019-12-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
|
IL319456A
(en)
|
2018-06-20 |
2025-05-01 |
Incyte Holdings Corp |
ANTI-PD-1 ANTIBODIES AND THEIR USES
|
|
US11274111B2
(en)
|
2018-06-20 |
2022-03-15 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
TW202504917A
(zh)
|
2018-06-21 |
2025-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
|
|
WO2020005068A2
(en)
|
2018-06-29 |
2020-01-02 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
US11161850B2
(en)
|
2018-07-05 |
2021-11-02 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
SG11202100208VA
(en)
|
2018-07-09 |
2021-02-25 |
Precigen Inc |
Fusion constructs and methods of using thereof
|
|
CA3105942A1
(en)
|
2018-07-09 |
2020-01-16 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
LT3820573T
(lt)
|
2018-07-10 |
2023-11-10 |
Novartis Ag |
3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diono dariniai ir jų naudojimas gydyti nuo ikaros šeimos cinko pirštų 2 (ikzf2) priklausomas ligas
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
KR102869944B1
(ko)
|
2018-07-11 |
2025-10-15 |
액팀 테라퓨틱스, 인코퍼레이티드 |
조작된 면역자극성 박테리아 균주 및 이의 용도
|
|
US20210277135A1
(en)
|
2018-07-13 |
2021-09-09 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
|
|
CN112424231B
(zh)
|
2018-07-19 |
2022-09-13 |
大有华夏生物医药集团有限公司 |
抗pd-1抗体及其剂量和用途
|
|
WO2020023268A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
CN108948202A
(zh)
*
|
2018-07-25 |
2018-12-07 |
博奥信生物技术(南京)有限公司 |
一种抗人pd1单克隆抗体及其用途
|
|
CN109053889B
(zh)
*
|
2018-07-25 |
2019-06-21 |
博奥信生物技术(南京)有限公司 |
一种抗人pd1单克隆抗体及用途
|
|
CA3107660A1
(en)
|
2018-07-26 |
2020-01-30 |
Bristol-Myers Squibb Company |
Lag-3 combination therapy for the treatment of cancer
|
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
|
US20210236633A1
(en)
|
2018-08-06 |
2021-08-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
ES2974964T3
(es)
|
2018-08-16 |
2024-07-02 |
Innate Tumor Immunity Inc |
Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
|
|
KR102768379B1
(ko)
|
2018-08-16 |
2025-02-13 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
|
|
JP2021534180A
(ja)
|
2018-08-16 |
2021-12-09 |
イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. |
置換4−アミノ−1H−イミダゾ[4,5−c]キノリン化合物およびその製造の改良法
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
CA3106881A1
(en)
|
2018-08-27 |
2020-03-05 |
Pieris Pharmaceuticals Gmbh |
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
|
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
|
AU2019336197A1
(en)
|
2018-09-07 |
2021-02-18 |
Pfizer Inc. |
Anti-avb8 antibodies and compositions and uses thereof
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
US11234986B2
(en)
|
2018-09-11 |
2022-02-01 |
Curis, Inc. |
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
|
US11072610B2
(en)
|
2018-09-12 |
2021-07-27 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
|
WO2020055702A1
(en)
|
2018-09-13 |
2020-03-19 |
Merck Sharp & Dohme Corp. |
Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
EP3853247A2
(en)
|
2018-09-19 |
2021-07-28 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
|
AU2019342749B2
(en)
|
2018-09-20 |
2025-07-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
JP6800191B2
(ja)
*
|
2018-09-21 |
2020-12-16 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗pd−1抗体並びにその治療及び診断のための使用
|
|
CA3114038A1
(en)
|
2018-09-25 |
2020-04-02 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
CN113164777B
(zh)
|
2018-09-27 |
2024-12-13 |
马伦戈治疗公司 |
Csf1r/ccr2多特异性抗体
|
|
EP3856779A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd22 chimeric antigen receptor (car) therapies
|
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
EP3856345A1
(en)
|
2018-09-29 |
2021-08-04 |
Novartis AG |
Process of manufacture of a compound for inhibiting the activity of shp2
|
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
WO2020076799A1
(en)
|
2018-10-09 |
2020-04-16 |
Bristol-Myers Squibb Company |
Anti-mertk antibodies for treating cancer
|
|
TWI855000B
(zh)
|
2018-10-11 |
2024-09-11 |
日商小野藥品工業股份有限公司 |
Sting促效化合物
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
KR20210091710A
(ko)
|
2018-10-12 |
2021-07-22 |
젠코어 인코포레이티드 |
PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도
|
|
AU2019361923A1
(en)
*
|
2018-10-15 |
2021-06-03 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
JP2022504905A
(ja)
|
2018-10-16 |
2022-01-13 |
ノバルティス アーゲー |
標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
|
|
US12152019B2
(en)
|
2018-10-17 |
2024-11-26 |
Merck Sharp & Dohme Llc |
Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
CN113164600A
(zh)
|
2018-10-17 |
2021-07-23 |
百欧林纳克斯有限公司 |
转移性胰脏腺癌的治疗
|
|
JP7595569B2
(ja)
|
2018-10-18 |
2024-12-06 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
固形腫瘍の処置のためのβig-h3アンタゴニストと免疫チェックポイント阻害剤との組み合わせ
|
|
HRP20241325T1
(hr)
|
2018-10-19 |
2024-12-20 |
Bristol-Myers Squibb Company |
Kombinirana terapija za melanom
|
|
CN113453715A
(zh)
|
2018-10-22 |
2021-09-28 |
葛兰素史克知识产权开发有限公司 |
给药
|
|
CN112912403A
(zh)
|
2018-10-23 |
2021-06-04 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
KR20210084546A
(ko)
|
2018-10-29 |
2021-07-07 |
메르사나 테라퓨틱스, 인코포레이티드 |
펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
|
EP3873464B1
(en)
|
2018-11-01 |
2025-07-30 |
Merck Sharp & Dohme LLC |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
AU2019372331A1
(en)
|
2018-11-01 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
US12065438B2
(en)
|
2018-11-06 |
2024-08-20 |
Merck Sharp & Dohme Llc |
Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
AU2019377456A1
(en)
|
2018-11-07 |
2021-05-27 |
Merck Sharp & Dohme Llc |
Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
US20220001026A1
(en)
|
2018-11-08 |
2022-01-06 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
|
EP3890773A4
(en)
|
2018-11-08 |
2022-11-09 |
Orionis Biosciences, Inc. |
MODULATION OF DENDRITIC CELL LINES
|
|
JP2022512973A
(ja)
|
2018-11-09 |
2022-02-07 |
ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー |
腫瘍微小環境の組成を測定するための方法及び組成物
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
SMT202400252T1
(it)
|
2018-11-14 |
2024-07-09 |
Regeneron Pharma |
Somministrazione intralesionale di inibitori di pd-1 il trattamentodel cancro della pelle.
|
|
JP7621943B2
(ja)
|
2018-11-14 |
2025-01-27 |
ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ |
がんを治療するための、抗ceacam6および抗pd-1抗体または抗pd-l1抗体のいずれかの医薬組み合わせ
|
|
CN113365650A
(zh)
|
2018-11-16 |
2021-09-07 |
新免疫技术有限公司 |
用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
|
|
TW202038951A
(zh)
|
2018-11-16 |
2020-11-01 |
美商亞闊股份有限公司 |
用於治療癌症之醫藥組合
|
|
WO2020102501A1
(en)
|
2018-11-16 |
2020-05-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a antibodies and uses thereof
|
|
CN113271963A
(zh)
|
2018-11-16 |
2021-08-17 |
朱诺治疗学股份有限公司 |
给予工程化t细胞以治疗b细胞恶性肿瘤的方法
|
|
CN113286813A
(zh)
|
2018-11-19 |
2021-08-20 |
得克萨斯大学体系董事会 |
用于car和tcr转导的模块化多顺反子载体
|
|
CN113015530A
(zh)
|
2018-11-20 |
2021-06-22 |
默沙东公司 |
取代的氨基三唑并嘧啶和氨基三唑并吡嗪腺苷受体拮抗剂、药物组合物及其用途
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
MX2021005808A
(es)
|
2018-11-20 |
2021-07-02 |
Univ Cornell |
Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
|
|
US12414952B2
(en)
|
2018-11-20 |
2025-09-16 |
Merck Sharp & Dohme Llc |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
CN113453678A
(zh)
|
2018-11-26 |
2021-09-28 |
德彪药业国际股份公司 |
Hiv感染的联合治疗
|
|
JP7491220B2
(ja)
|
2018-11-27 |
2024-05-28 |
小野薬品工業株式会社 |
免疫チェックポイント阻害薬およびfolfirinox療法との併用によるがん治療
|
|
EP3886845B1
(en)
|
2018-11-28 |
2024-09-04 |
Merck Sharp & Dohme LLC |
Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
|
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
MX2021006393A
(es)
|
2018-11-29 |
2021-10-13 |
Univ Texas |
Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
|
|
EP3887548A1
(en)
|
2018-11-30 |
2021-10-06 |
GBG Forschungs GmbH |
Method for predicting the response to cancer immunotherapy in cancer patients
|
|
CA3120869A1
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
IL283487B2
(en)
|
2018-11-30 |
2024-07-01 |
Glaxosmithkline Ip Dev Ltd |
Compounds useful in hiv therapy
|
|
WO2020112700A1
(en)
|
2018-11-30 |
2020-06-04 |
Merck Sharp & Dohme Corp. |
9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
AU2019392090A1
(en)
|
2018-12-03 |
2021-06-17 |
Agensys, Inc. |
Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
|
|
JP7584418B2
(ja)
|
2018-12-04 |
2024-11-15 |
ブリストル-マイヤーズ スクイブ カンパニー |
多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
|
|
JP2022511029A
(ja)
|
2018-12-04 |
2022-01-28 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
がんの処置のための薬剤としての使用のためのcdk9インヒビターおよびその多形
|
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
MA54448A
(fr)
|
2018-12-11 |
2021-10-20 |
Theravance Biopharma R&D Ip Llc |
Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
|
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
|
BR112021011393A2
(pt)
|
2018-12-13 |
2021-08-31 |
Surface Oncology, Inc. |
Anticorpos anti-il-27 e usos dos mesmos
|
|
EP3897622B1
(en)
|
2018-12-18 |
2026-01-14 |
Merck Sharp & Dohme LLC |
Arginase inhibitors and methods of use
|
|
CN113164778B
(zh)
|
2018-12-19 |
2024-07-26 |
拜耳公司 |
抗ceacam6和tim3抗体的药物组合
|
|
US20220064332A1
(en)
|
2018-12-19 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
|
AU2019408408A1
(en)
|
2018-12-21 |
2021-06-03 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
MX2021007565A
(es)
|
2018-12-21 |
2021-10-13 |
Aim Immunotech Inc |
Composiciones y metodos para la terapia contra el cancer.
|
|
AU2019409132A1
(en)
|
2018-12-21 |
2021-07-15 |
Novartis Ag |
Antibodies to PMEL17 and conjugates thereof
|
|
EP3899951A1
(en)
|
2018-12-23 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Tumor classification based on predicted tumor mutational burden
|
|
US12364723B2
(en)
|
2018-12-27 |
2025-07-22 |
Amgen Inc. |
Thermostable compositions comprising live attenuated herpes simplex virus type 1
|
|
JP2022517324A
(ja)
|
2019-01-03 |
2022-03-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
癌を患っている被験者における、cd8陽性t細胞依存性免疫応答を増強させるための方法及び医薬組成物
|
|
SG11202107413YA
(en)
|
2019-01-09 |
2021-08-30 |
Celgene Corp |
Antiproliferative compounds and second active agents for use in treating multiple myeloma
|
|
FI3908582T3
(fi)
|
2019-01-09 |
2026-01-27 |
Celgene Corp |
Kiinteitä muotoja, joka käsittävät (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-4-yyli)oksi)metyyli)bensyyli)piperatsin-1-yyli)-3-fluoribentsonitriiliä ja sen suoloja, ja niitä käsittäviä koostumuksia ja niiden käyttömenetelmiä
|
|
WO2020146441A1
(en)
|
2019-01-09 |
2020-07-16 |
Celgene Corporation |
Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
|
|
CN111423510B
(zh)
|
2019-01-10 |
2024-02-06 |
迈威(上海)生物科技股份有限公司 |
重组抗人pd-1抗体及其应用
|
|
CN113286787A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
WO2020150114A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Heterocyclic nlrp3 modulators, for use in the treatment of cancer
|
|
KR102903509B1
(ko)
|
2019-01-14 |
2025-12-22 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
암의 치료에 사용하기 위한 nlrp3-조정제로서의 치환된 퀴나졸린
|
|
CN113286786A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
AU2020208637A1
(en)
|
2019-01-18 |
2021-09-09 |
Dracen Pharmaceuticals, Inc. |
Combinaton therapy with a don prodrug and an immune checkpoint inhibitor
|
|
AU2020210614A1
(en)
|
2019-01-21 |
2021-08-26 |
Sanofi |
Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers
|
|
TWI894135B
(zh)
|
2019-01-25 |
2025-08-21 |
德商百靈佳殷格翰國際股份有限公司 |
編碼ccl21之重組棒狀病毒
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020160050A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
JP7442536B2
(ja)
|
2019-01-30 |
2024-03-04 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを患っている被験体が免疫チェックポイント阻害剤で反応を達成するかを特定するための方法及び組成物
|
|
CN113795512A
(zh)
|
2019-02-01 |
2021-12-14 |
葛兰素史克知识产权开发有限公司 |
包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
|
|
EP3921031A1
(en)
|
2019-02-04 |
2021-12-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for modulating blood-brain barrier
|
|
BR112021015487A2
(pt)
|
2019-02-12 |
2021-10-05 |
Novartis Ag |
Combinação farmacêutica que compreende tno155 e um inibidor de pd-1
|
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
EP3924520A1
(en)
|
2019-02-13 |
2021-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
MX2021009764A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
|
|
MX2021009763A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
|
|
PH12021551976A1
(en)
|
2019-02-15 |
2022-07-04 |
Incyte Corp |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
|
US20220107320A1
(en)
|
2019-02-15 |
2022-04-07 |
Incelldx, Inc. |
Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
CN113710270A
(zh)
|
2019-02-19 |
2021-11-26 |
迈斯特治疗公司 |
产生可用于治疗癌症的自体t细胞的方法及其组合物
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
CN113544271B
(zh)
|
2019-02-27 |
2025-07-11 |
Ionis制药公司 |
Malat1表达的调节剂
|
|
JP2022521800A
(ja)
|
2019-02-28 |
2022-04-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
皮膚がんを治療するためのpd-1阻害剤の投与
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
AU2020232264A1
(en)
|
2019-03-05 |
2021-08-26 |
Amgen Inc. |
Use of oncolytic viruses for the treatment of cancer
|
|
MA55204A
(fr)
|
2019-03-06 |
2022-01-12 |
Regeneron Pharma |
Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
KR20210141539A
(ko)
|
2019-03-13 |
2021-11-23 |
머크 샤프 앤드 돔 코포레이션 |
Ctla-4 및 pd-1 차단제를 포함하는 항암 조합 요법
|
|
WO2020183011A1
(en)
|
2019-03-14 |
2020-09-17 |
Institut Curie |
Htr1d inhibitors and uses thereof in the treatment of cancer
|
|
WO2020191084A1
(en)
|
2019-03-18 |
2020-09-24 |
The Regents Of The University Of California |
Augmentation of t-cell activation by oscillatory forces and engineered antigen-presenting cells
|
|
US20220152179A1
(en)
|
2019-03-19 |
2022-05-19 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
|
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
|
CN113747895A
(zh)
|
2019-03-22 |
2021-12-03 |
大日本住友制药肿瘤公司 |
包含pkm2调节剂的组合物和用其治疗的方法
|
|
JP2022527298A
(ja)
|
2019-03-26 |
2022-06-01 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Stat3の低分子分解誘導剤
|
|
CN113891748A
(zh)
|
2019-03-28 |
2022-01-04 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
TW202102543A
(zh)
|
2019-03-29 |
2021-01-16 |
美商安進公司 |
溶瘤病毒在癌症新輔助療法中之用途
|
|
JP7760374B2
(ja)
|
2019-03-29 |
2025-10-27 |
ターンストーン バイオロジクス コーポレイション |
T細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
|
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
|
EP3947403A1
(en)
|
2019-03-29 |
2022-02-09 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
|
IL286711B2
(en)
|
2019-03-29 |
2025-10-01 |
Inst Curie |
Interleukin 2 variants with different biological activities
|
|
WO2020201568A1
(en)
|
2019-04-03 |
2020-10-08 |
Targimmune Therapeutics Ag |
Immunotherapy for the treatment of cancer
|
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
AR118619A1
(es)
*
|
2019-04-10 |
2021-10-20 |
Bio Thera Solutions Ltd |
Anticuerpos de unión a pd-1
|
|
BR112021020148A2
(pt)
*
|
2019-04-11 |
2021-12-21 |
Bayer Ag |
Combinações de anticorpos anti-ildr2 e antagonistas pd-1
|
|
BR112021020225A2
(pt)
|
2019-04-12 |
2021-12-07 |
Vascular Biogenics Ltd |
Métodos de terapia antitumoral
|
|
WO2020214957A1
(en)
*
|
2019-04-19 |
2020-10-22 |
Tcrcure Biopharma Corp. |
Anti-pd-1 antibodies and uses thereof
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
WO2020225552A1
(en)
|
2019-05-06 |
2020-11-12 |
Medimmune Limited |
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
|
KR20220012261A
(ko)
|
2019-05-07 |
2022-02-03 |
이뮤니컴 인코포레이티드 |
체외 성분채집술에 의한 체크포인트 억제제에 대한 반응 증가
|
|
WO2020227711A1
(en)
|
2019-05-09 |
2020-11-12 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
|
CN113825527A
(zh)
|
2019-05-13 |
2021-12-21 |
瑞泽恩制药公司 |
用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
|
|
EP3969043A1
(en)
|
2019-05-15 |
2022-03-23 |
Neotx Therapeutics Ltd. |
Cancer treatment
|
|
EP3969438A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
|
JP2022533194A
(ja)
|
2019-05-16 |
2022-07-21 |
スティングセラ インコーポレイテッド |
ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法
|
|
WO2020236667A1
(en)
|
2019-05-17 |
2020-11-26 |
Gb006, Inc. |
Methods of treating cancer
|
|
JP2022532766A
(ja)
|
2019-05-17 |
2022-07-19 |
キャンサー プリベンション ファーマシューティカルズ,インコーポレイテッド |
家族性腺腫性ポリポーシスを処置するための方法
|
|
IL266728B
(en)
|
2019-05-19 |
2020-11-30 |
Yeda Res & Dev |
Identification of recurrent mutant neopeptides
|
|
US20210317143A9
(en)
|
2019-05-20 |
2021-10-14 |
Massachusetts Institute Of Technology |
Boronic ester prodrugs and uses thereof
|
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Cdk阻害剤を使用した組合せ療法
|
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
|
WO2020243563A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures for suitability to immuno-oncology therapy
|
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
US20220298225A1
(en)
|
2019-06-03 |
2022-09-22 |
The University Of Chicago |
Methods and compositions for treating cancer with collagen binding drug carriers
|
|
US20220305135A1
(en)
|
2019-06-03 |
2022-09-29 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
US20220304984A1
(en)
|
2019-06-12 |
2022-09-29 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
|
US20220265590A1
(en)
|
2019-06-12 |
2022-08-25 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
|
JP2022536929A
(ja)
|
2019-06-14 |
2022-08-22 |
ティルト バイオセラピューティクス オサケユキチュア |
腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法
|
|
WO2020255011A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
KR20220041079A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합
|
|
CN115443329A
(zh)
|
2019-06-27 |
2022-12-06 |
乔治华盛顿大学国会特许非营利公司 |
Hdac6激活的巨噬细胞、其组合物及用途
|
|
WO2020260547A1
(en)
|
2019-06-27 |
2020-12-30 |
Rigontec Gmbh |
Design method for optimized rig-i ligands
|
|
EP3994270A1
(en)
|
2019-07-02 |
2022-05-11 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
|
JP2022539208A
(ja)
|
2019-07-03 |
2022-09-07 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用
|
|
TWI889320B
(zh)
|
2019-07-05 |
2025-07-01 |
日商小野藥品工業股份有限公司 |
以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
BR112022000713A2
(pt)
|
2019-07-16 |
2022-03-22 |
Univ Michigan Regents |
Imidazopirimidinas como inibidores de eed e o uso das mesmas
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
WO2021019526A1
(en)
|
2019-07-29 |
2021-02-04 |
Yeda Research And Development Co. Ltd. |
Methods of treating and diagnosing lung cancer
|
|
WO2021021767A1
(en)
*
|
2019-07-30 |
2021-02-04 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bispecific antibodies
|
|
WO2021023698A1
(en)
|
2019-08-02 |
2021-02-11 |
Lanthiopep B.V |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
JP2022543086A
(ja)
|
2019-08-02 |
2022-10-07 |
メルサナ セラピューティクス インコーポレイテッド |
がんの処置用のSTING(インターフェロン遺伝子刺激因子)アゴニストとしてのビス-[N-((5-カルバモイル)-1H-ベンゾ[d]イミダゾール-2-イル)-ピラゾール-5-カルボキサミド]誘導体および関連化合物
|
|
PH12022550244A1
(en)
|
2019-08-05 |
2022-12-12 |
Nat Cancer Ct |
Biomarkers for determining the efficacy of immune checkpoint inhibitors
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021025140A1
(ja)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
CN119409834A
(zh)
|
2019-08-12 |
2025-02-11 |
北京恩瑞尼生物科技股份有限公司 |
用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
|
|
BR112022002698A2
(pt)
|
2019-08-14 |
2022-07-19 |
Incyte Corp |
Compostos de imidazolil pirimidinilamina como inibidores de cdk2
|
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
|
KR102231974B1
(ko)
*
|
2019-08-23 |
2021-03-25 |
한국과학기술원 |
사람의 프로그램된 세포사멸 단백질(pd-1)에 선택적으로 결합하는 신규한 폴리펩티드 및 이의 용도
|
|
US20220305048A1
(en)
|
2019-08-26 |
2022-09-29 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
|
JP2022545735A
(ja)
|
2019-08-27 |
2022-10-28 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
セレブロンe3リガーゼ阻害剤
|
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
US12121565B2
(en)
|
2019-09-13 |
2024-10-22 |
Duke University |
Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
|
|
US20220372160A1
(en)
|
2019-09-16 |
2022-11-24 |
Surface Oncology, Inc. |
Anti-CD39 Antibody Compositions and Methods
|
|
CA3150906A1
(en)
|
2019-09-17 |
2021-03-25 |
Renato T. Skerlj |
Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
|
|
KR20220100858A
(ko)
|
2019-09-17 |
2022-07-18 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
치환된 이미다졸 카르복사미드, 및 질병의 치료에서의 이의 용도
|
|
US20220402901A1
(en)
|
2019-09-17 |
2022-12-22 |
Bial - R&D Investments, S.A. |
Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
|
|
JOP20220068A1
(ar)
|
2019-09-18 |
2023-01-30 |
Novartis Ag |
بروتينات اندماج nkg2d واستخداماتها
|
|
WO2021053587A1
(en)
|
2019-09-18 |
2021-03-25 |
Klaus Strein |
Bispecific antibodies against ceacam5 and cd3
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
US20220380368A1
(en)
|
2019-09-19 |
2022-12-01 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
|
CA3153777A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
EP4034123A4
(en)
|
2019-09-24 |
2023-11-01 |
Mirati Therapeutics, Inc. |
COMBINATION THERAPIES
|
|
EP4034154A1
(en)
|
2019-09-25 |
2022-08-03 |
Seagen Inc. |
Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
|
|
CN115087671A
(zh)
|
2019-09-25 |
2022-09-20 |
表面肿瘤学公司 |
抗il-27抗体及其用途
|
|
BR112022005655A2
(pt)
|
2019-09-25 |
2022-09-06 |
Bristol Myers Squibb Co |
Biomarcador compósito para terapia para câncer
|
|
CN120842223A
(zh)
|
2019-09-26 |
2025-10-28 |
诺华股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
|
CA3155173A1
(en)
|
2019-09-27 |
2021-04-01 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
IL291471B2
(en)
|
2019-09-30 |
2025-04-01 |
Incyte Corp |
Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
|
|
WO2021067644A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US20220354811A1
(en)
|
2019-10-03 |
2022-11-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
|
CN115916233A
(zh)
|
2019-10-03 |
2023-04-04 |
Xencor股份有限公司 |
靶向IL-12异源二聚体Fc融合蛋白
|
|
BR112022006977A2
(pt)
|
2019-10-11 |
2022-09-20 |
Incyte Corp |
Aminas bicíclicas como inibidores de cdk2
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
GB201914747D0
(en)
|
2019-10-11 |
2019-11-27 |
Ultrahuman Eight Ltd |
PD1 and vegfr2 dual-binding agents
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12380963B2
(en)
|
2019-10-14 |
2025-08-05 |
The Medical College Of Wisconsin, Inc. |
Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021074391A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
|
IL292347A
(en)
|
2019-10-21 |
2022-06-01 |
Novartis Ag |
Combination treatments with ventoclax and tim-3 inhibitors
|
|
US20220401539A1
(en)
|
2019-10-22 |
2022-12-22 |
Institut Curie |
Immunotherapy Targeting Tumor Neoantigenic Peptides
|
|
EP4048795A1
(en)
|
2019-10-23 |
2022-08-31 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
|
CN114630679A
(zh)
|
2019-10-25 |
2022-06-14 |
第一三共株式会社 |
抗garp抗体和免疫调节剂的组合
|
|
NL2024108B1
(en)
|
2019-10-26 |
2021-07-19 |
Vitroscan B V |
Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses
|
|
KR20220100607A
(ko)
|
2019-10-28 |
2022-07-15 |
상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 |
5원 헤테로사이클릭 옥소카르복실산 화합물 및 이의 의약 용도
|
|
AU2020374883A1
(en)
|
2019-10-29 |
2022-05-26 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist, a VEGFR/FGFR/RET tyrosine kinase inhibitor and a CBP/beta-catenin inhibitor for treating cancer
|
|
US20240122938A1
(en)
|
2019-10-29 |
2024-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating uveal melanoma
|
|
WO2021087105A1
(en)
|
2019-10-30 |
2021-05-06 |
Duke University |
Immunotherapy with combination therapy comprising an immunotoxin
|
|
WO2021087458A2
(en)
|
2019-11-02 |
2021-05-06 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
CN114846135A
(zh)
|
2019-11-04 |
2022-08-02 |
杜克大学 |
原发性和转移性癌症的治疗
|
|
WO2021092044A1
(en)
|
2019-11-05 |
2021-05-14 |
Bristol-Myers Squibb Company |
M-protein assays and uses thereof
|
|
IL292765A
(en)
|
2019-11-05 |
2022-07-01 |
Celgene Corp |
Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
KR20220113685A
(ko)
|
2019-11-07 |
2022-08-16 |
젠맵 에이/에스 |
항-pd-1 항체와 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
|
|
AU2020378280A1
(en)
|
2019-11-07 |
2022-04-07 |
Feng Biosciences, Ltd. |
Classification of tumor microenvironments
|
|
BR112022008191A2
(pt)
|
2019-11-08 |
2022-07-12 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para melanoma
|
|
CN114829366A
(zh)
|
2019-11-11 |
2022-07-29 |
因赛特公司 |
Pd-1/pd-l1抑制剂的盐及结晶形式
|
|
WO2021096888A1
(en)
|
2019-11-12 |
2021-05-20 |
Foundation Medicine, Inc. |
Methods of detecting a fusion gene encoding a neoantigen
|
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
CA3160307A1
(en)
|
2019-11-22 |
2021-05-27 |
Theravance Biopharma R&D Ip, Llc |
Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
|
|
EP3824954A1
(en)
|
2019-11-22 |
2021-05-26 |
Centre National de la Recherche Scientifique |
Device, apparatus and method for minibeam radiation therapy
|
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
CA3162892A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
EP4066852A4
(en)
|
2019-11-27 |
2024-05-22 |
NEC Corporation |
PHARMACEUTICAL COMPOSITION
|
|
JP2023504042A
(ja)
|
2019-11-27 |
2023-02-01 |
ミスト セラピューティクス リミテッド ライアビリティ カンパニー |
調節物質を使用した腫瘍反応性t細胞組成物の生成方法
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
IL293001A
(en)
|
2019-12-04 |
2022-07-01 |
Incyte Corp |
Derivatives of fgfr repressors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
US20230074558A1
(en)
|
2019-12-06 |
2023-03-09 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
BR112022011268A2
(pt)
|
2019-12-09 |
2022-09-06 |
Seagen Inc |
Terapia de combinação com antagonista de liv1-adc e pd1
|
|
KR20220115803A
(ko)
|
2019-12-13 |
2022-08-18 |
삼성바이오에피스 주식회사 |
안정한 항-pd-1 항체 약제학적 제제
|
|
WO2021122434A1
(en)
|
2019-12-16 |
2021-06-24 |
Bayer Aktiengesellschaft |
Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer
|
|
US20220396577A1
(en)
|
2019-12-17 |
2022-12-15 |
Merck Sharp & Dohme Llc |
Novel substituted 1,3-8-triazaspiro[4,5] decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
|
|
EP4076434A1
(en)
|
2019-12-17 |
2022-10-26 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
AU2020409429A1
(en)
|
2019-12-18 |
2022-06-16 |
Ctxt Pty Ltd |
Compounds
|
|
WO2021123243A1
(en)
|
2019-12-19 |
2021-06-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
|
AU2020407130A1
(en)
|
2019-12-19 |
2022-06-16 |
Bristol-Myers Squibb Company |
Combinations of DGK inhibitors and checkpoint antagonists
|
|
JP2023507190A
(ja)
|
2019-12-20 |
2023-02-21 |
ノバルティス アーゲー |
増殖性疾患を治療するための抗TGFβ抗体及びチェックポイント阻害薬の使用
|
|
US20230044381A1
(en)
*
|
2019-12-20 |
2023-02-09 |
Guangdong Feipeng Pharmaceutical Co., Ltd |
Anti-human programmed death-1 monoclonal antibody
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
US20210205311A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
|
|
US20230140132A1
(en)
|
2020-01-07 |
2023-05-04 |
Merck Sharp & Dohme Llc |
Arginase inhibitors and methods of use
|
|
AU2021206202A1
(en)
|
2020-01-07 |
2022-06-30 |
Board Of Regents, The University Of Texas System |
Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
|
|
JP7573622B2
(ja)
|
2020-01-10 |
2024-10-25 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Nlrp3モジュレーター
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021144657A1
(en)
|
2020-01-17 |
2021-07-22 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
US20230076415A1
(en)
|
2020-01-17 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
KR20220133238A
(ko)
|
2020-01-29 |
2022-10-04 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
|
|
KR20220132555A
(ko)
|
2020-01-29 |
2022-09-30 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Nrg1 융합체를 사용한 암 치료를 위한 egfr/her2 티로신 키나제 억제제 및/또는 her2/her3 항체의 사용
|
|
KR20210097882A
(ko)
|
2020-01-30 |
2021-08-10 |
삼성바이오에피스 주식회사 |
안정한 항-pd-1 항체 약제학적 제제
|
|
MX2022009270A
(es)
|
2020-01-30 |
2022-10-27 |
Ona Therapeutics S L |
Un inhibidor de cd36 para usarse en una terapia combinada para el tratamiento de cáncer y la metástasis del cáncer.
|
|
EP4100126A1
(en)
|
2020-02-05 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
|
KR20220139915A
(ko)
|
2020-02-06 |
2022-10-17 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-10 및 그의 용도
|
|
US20230106973A1
(en)
|
2020-02-17 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
CA3173257A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
EP4110799B1
(en)
|
2020-02-27 |
2024-11-06 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
TW202146452A
(zh)
|
2020-02-28 |
2021-12-16 |
瑞士商諾華公司 |
結合cd123和cd3之雙特異性抗體的給藥
|
|
AU2021225491A1
(en)
|
2020-02-28 |
2022-10-20 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
|
|
EP4110955A1
(en)
|
2020-02-28 |
2023-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
|
KR20220150353A
(ko)
|
2020-03-05 |
2022-11-10 |
네오티엑스 테라퓨틱스 엘티디. |
면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
|
|
US20230114276A1
(en)
*
|
2020-03-06 |
2023-04-13 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Modulating anti-tumor immunity
|
|
CA3170456A1
(en)
|
2020-03-06 |
2021-09-10 |
Ellen Filvaroff |
Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
|
|
AU2021230385A1
(en)
|
2020-03-06 |
2022-09-22 |
Incyte Corporation |
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
|
|
BR112022016720A2
(pt)
|
2020-03-06 |
2022-11-16 |
Ona Therapeutics S L |
Anticorpos anti-cd36 e seu uso para tratamento de câncer
|
|
EP3878446A1
(en)
|
2020-03-09 |
2021-09-15 |
Universite De Geneve |
Hsd11b1 inhibitors for use in immunotherapy and uses thereof
|
|
WO2021183318A2
(en)
|
2020-03-09 |
2021-09-16 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
|
IL296673A
(en)
|
2020-03-23 |
2022-11-01 |
Bristol Myers Squibb Co |
Anti-ccr8 antibodies for treating cancer
|
|
WO2021195481A1
(en)
|
2020-03-26 |
2021-09-30 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
|
EP4127139A1
(en)
|
2020-03-27 |
2023-02-08 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
CA3169487A1
(en)
|
2020-03-30 |
2021-10-07 |
Richard PHILIPSON |
Compositions and methods for treating cancer
|
|
CN113461824A
(zh)
|
2020-03-31 |
2021-10-01 |
普米斯生物技术(珠海)有限公司 |
一种构建多特异性抗体的平台
|
|
JP2023519673A
(ja)
|
2020-03-31 |
2023-05-12 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
置換ピリミジンおよび使用方法
|
|
CA3174297A1
(en)
|
2020-04-02 |
2021-10-07 |
Jeremy R. Duvall |
Antibody drug conjugates comprising sting agonists
|
|
WO2021205444A1
(en)
|
2020-04-06 |
2021-10-14 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing cancer and predicting responsiveness to therapy
|
|
EP4134134A4
(en)
|
2020-04-10 |
2023-12-27 |
ONO Pharmaceutical Co., Ltd. |
STING AGONISTIC COMPOUND
|
|
AU2021251265A1
(en)
|
2020-04-10 |
2022-11-03 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
|
|
JPWO2021206158A1
(pt)
|
2020-04-10 |
2021-10-14 |
|
|
|
CN115698075A
(zh)
|
2020-04-14 |
2023-02-03 |
葛兰素史密斯克莱知识产权发展有限公司 |
涉及抗icos和抗pd1抗体,任选地进一步涉及抗tim3抗体的癌症的组合治疗
|
|
AU2021257570A1
(en)
|
2020-04-14 |
2022-11-03 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
MX2022012780A
(es)
|
2020-04-16 |
2023-01-18 |
Incyte Corp |
Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
|
|
TW202200137A
(zh)
|
2020-04-21 |
2022-01-01 |
瑞士商諾華公司 |
用於治療由csf-1r調節的疾病之給藥方案
|
|
IL297442A
(en)
|
2020-04-22 |
2022-12-01 |
Iovance Biotherapeutics Inc |
Systems and methods for coordinating production of cells for patient-specific immunotherapy
|
|
CA3176515A1
(en)
|
2020-04-22 |
2021-10-28 |
Merck Sharp & Dohme Llc |
Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer
|
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
PE20221894A1
(es)
|
2020-05-01 |
2022-12-13 |
Ngm Biopharmaceuticals Inc |
Agentes de union a ilt y metodos para su uso
|
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
|
JP7804588B2
(ja)
|
2020-05-05 |
2026-01-22 |
テオン セラピューティクス,インク. |
カンナビノイド受容体2型(cb2)調節物質及びその使用
|
|
US12454525B2
(en)
|
2020-05-06 |
2025-10-28 |
Merck Sharp & Dohme Llc |
IL4I1 inhibitors and methods of use
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
PE20230784A1
(es)
|
2020-05-19 |
2023-05-11 |
Boehringer Ingelheim Int |
Moleculas de fijacion para el tratamiento de cancer
|
|
EP4153628A1
(en)
|
2020-05-20 |
2023-03-29 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
|
AU2021275239A1
(en)
|
2020-05-21 |
2022-12-15 |
Board Of Regents, The University Of Texas System |
T cell receptors with VGLL1 specificity and uses thereof
|
|
US20210403567A1
(en)
|
2020-05-26 |
2021-12-30 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cervical cancer by administering a pd-1 inhibitor
|
|
WO2021243207A1
(en)
|
2020-05-28 |
2021-12-02 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
|
US20230173095A1
(en)
|
2020-05-29 |
2023-06-08 |
President And Fellows Of Harvard College |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
|
EP4162037A1
(en)
|
2020-06-03 |
2023-04-12 |
MV Biotherapeutics SA |
Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
|
JP7565384B2
(ja)
|
2020-06-03 |
2024-10-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
CD80細胞外ドメインFc融合タンパク質をコードするリコンビナントラブドウイルス
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
TW202214623A
(zh)
|
2020-06-10 |
2022-04-16 |
美商施萬生物製藥研發 Ip有限責任公司 |
結晶型alk5抑制劑及其用途
|
|
IL298473A
(en)
|
2020-06-11 |
2023-01-01 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2021262969A1
(en)
|
2020-06-24 |
2021-12-30 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
WO2021260443A1
(en)
|
2020-06-24 |
2021-12-30 |
Bayer Aktiengesellschaft |
Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines
|
|
BR112022026090A2
(pt)
|
2020-06-25 |
2023-01-17 |
Celgene Corp |
Métodos para tratar câncer com terapias de combinação
|
|
IL299149A
(en)
|
2020-06-26 |
2023-02-01 |
Amgen Inc |
IL-10 mutants and their related proteins
|
|
TW202216774A
(zh)
*
|
2020-06-26 |
2022-05-01 |
美商索倫多醫療公司 |
抗-pd1抗體及其用途
|
|
CA3184366A1
(en)
|
2020-06-29 |
2022-01-06 |
Darby Rye Schmidt |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
JP7741831B2
(ja)
|
2020-06-30 |
2025-09-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
術前補助療法及び根治手術後の固形がんを患っている患者の再発及び/又は死亡のリスクを予測するための方法
|
|
US20230235408A1
(en)
|
2020-06-30 |
2023-07-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
|
WO2022003568A1
(en)
|
2020-06-30 |
2022-01-06 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
AU2021306613A1
(en)
|
2020-07-07 |
2023-02-02 |
BioNTech SE |
Therapeutic RNA for HPV-positive cancer
|
|
HUE068476T2
(hu)
|
2020-07-07 |
2024-12-28 |
Celgene Corp |
(S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoizoindolin-4-il)oxi)metil)-benzil)piperazin-1-il) -3-fluorbenzonitrilt tartalmazó gyógyszerkészítmények és ezek alkalmlazása
|
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
|
WO2022011205A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
WO2022011204A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
|
IL299764A
(en)
|
2020-07-10 |
2023-03-01 |
Precigen Inc |
Fusion constructs and methods for using them
|
|
JP2023535610A
(ja)
|
2020-07-28 |
2023-08-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを予防及び処置するための方法及び組成物
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN116194480A
(zh)
|
2020-08-13 |
2023-05-30 |
百时美施贵宝公司 |
将il-2重定向到目的靶细胞的方法
|
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
|
CA3168743A1
(en)
|
2020-08-26 |
2022-03-03 |
Matthew G. Fury |
Methods of treating cancer by administering a pd-1 inhibitor
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
|
KR20230058442A
(ko)
|
2020-08-28 |
2023-05-03 |
브리스톨-마이어스 스큅 컴퍼니 |
간세포성 암종에 대한 lag-3 길항제 요법
|
|
US20230331848A1
(en)
*
|
2020-08-31 |
2023-10-19 |
Biosion Inc. |
Pd-1 binding antibodies and uses thereof
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204453A1
(en)
|
2020-08-31 |
2023-07-05 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
KR20230087451A
(ko)
|
2020-09-02 |
2023-06-16 |
주식회사 파멥신 |
암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법
|
|
AU2021337650A1
(en)
|
2020-09-03 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer pain by administering a pd-1 inhibitor
|
|
KR20230069956A
(ko)
|
2020-09-14 |
2023-05-19 |
베링거 인겔하임 인터내셔날 게엠베하 |
이종 프라임 부스트 백신
|
|
US20230365692A1
(en)
|
2020-09-24 |
2023-11-16 |
Merck Sharp & Dohme Llc |
Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
|
|
EP4221842A4
(en)
|
2020-10-02 |
2024-11-20 |
Dracen Pharmaceuticals, Inc. |
LYOPHILIZED COMPOSITION CONTAINING (S)-ISOPROPYL 2-((S)-2-ACETAMIDO-3-(1H-INDOL-3-YL)PROPANAMIDO)-6-DIAZO-5-OXOHEXANOATE FOR SUBCUTANEOUS ADMINISTRATION AND ITS USE
|
|
WO2022072762A1
(en)
|
2020-10-02 |
2022-04-07 |
Regeneron Pharmaceuticals, Inc. |
Combination of antibodies for treating cancer with reduced cytokine release syndrome
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
WO2022076318A1
(en)
|
2020-10-05 |
2022-04-14 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
|
CN116348142A
(zh)
|
2020-10-08 |
2023-06-27 |
塔尔格免疫治疗有限公司 |
用于治疗癌症的免疫疗法
|
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
|
CA3196243A1
(en)
|
2020-10-20 |
2022-04-28 |
Angela Marinetti |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
|
IL301907A
(en)
|
2020-10-23 |
2023-06-01 |
Bristol Myers Squibb Co |
Lag-3 antagonist therapy for lung cancer
|
|
MX2023004847A
(es)
|
2020-10-28 |
2023-07-11 |
Ikena Oncology Inc |
Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina.
|
|
TW202233185A
(zh)
|
2020-10-28 |
2022-09-01 |
日商衛材R&D企管股份有限公司 |
腫瘤治療用醫藥組合物
|
|
US20220133902A1
(en)
*
|
2020-11-04 |
2022-05-05 |
Heidelberg Pharma Research Gmbh |
Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy
|
|
CA3195572A1
(en)
|
2020-11-04 |
2022-05-12 |
Heidelberg Pharma Research Gmbh |
Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy
|
|
EP4240377A4
(en)
|
2020-11-05 |
2025-01-15 |
Board of Regents, The University of Texas System |
Engineered t cell receptors targeting egfr antigens and methods of use
|
|
US11866434B2
(en)
|
2020-11-06 |
2024-01-09 |
Incyte Corporation |
Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Pd—1/pd—l1抑制劑之結晶形式
|
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|
|
EP4240415A1
(en)
|
2020-11-08 |
2023-09-13 |
Seagen Inc. |
Combination-therapy antibody drug conjugate with immune cell inhibitor
|
|
US20230390303A1
(en)
|
2020-11-13 |
2023-12-07 |
Ono Pharmaceutical Co., Ltd. |
Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
|
|
IL302728A
(en)
|
2020-11-13 |
2023-07-01 |
Catamaran Bio Inc |
Genetically modified natural killer cells and methods of use thereof
|
|
WO2022101481A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
EP4244392A1
(en)
|
2020-11-16 |
2023-09-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
WO2022108931A2
(en)
|
2020-11-17 |
2022-05-27 |
Seagen Inc. |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
|
WO2022106505A1
(en)
|
2020-11-18 |
2022-05-27 |
Institut Curie |
Dimers of biguanidines and their therapeutic uses
|
|
WO2022115611A1
(en)
|
2020-11-25 |
2022-06-02 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
|
TWI877433B
(zh)
|
2020-11-30 |
2025-03-21 |
大陸商杭州阿諾生物醫藥科技有限公司 |
用於治療pik3ca突變癌症的組合療法
|
|
WO2022118197A1
(en)
|
2020-12-02 |
2022-06-09 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
US20240050432A1
(en)
|
2020-12-08 |
2024-02-15 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
AU2021400227A1
(en)
|
2020-12-18 |
2023-04-27 |
Lamkap Bio Beta Ltd |
Bispecific antibodies against ceacam5 and cd47
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
|
US20220233693A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Antibody Compositions and Methods of Use Thereof
|
|
US20220233689A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
|
TW202241441A
(zh)
|
2020-12-29 |
2022-11-01 |
美商英塞特公司 |
包含a2a/a2b抑制劑、pd-1/pd-l1抑制劑及抗cd73抗體之組合療法
|
|
JP2024503379A
(ja)
|
2021-01-08 |
2024-01-25 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗フコシルgm1抗体を使用した組み合わせ療法
|
|
CN117916271A
(zh)
|
2021-01-14 |
2024-04-19 |
居里研究所 |
Her2单域抗体变体及其car
|
|
CA3205538A1
(en)
|
2021-01-19 |
2022-07-28 |
Han XIAO |
Bone-specific delivery of polypeptides
|
|
CN116963773A
(zh)
|
2021-01-21 |
2023-10-27 |
浙江养生堂天然药物研究所有限公司 |
治疗肿瘤的组合物及方法
|
|
US12397055B2
(en)
|
2021-01-22 |
2025-08-26 |
Mendus B.V. |
Methods of tumor vaccination
|
|
CA3210196A1
(en)
|
2021-01-29 |
2022-08-04 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
EP4284834A1
(en)
|
2021-01-29 |
2023-12-06 |
Merck Sharp & Dohme LLC |
Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
|
EP4286520A4
(en)
*
|
2021-01-29 |
2025-04-16 |
Minghui Pharmaceutical (Hangzhou) Limited |
Antigen-binding protein and use thereof
|
|
EP4292596A4
(en)
|
2021-02-10 |
2025-03-19 |
Curon Biopharmaceutical (Shanghai) Co., Limited |
METHODS AND COMBINATIONS FOR THE TREATMENT OF TUMORS
|
|
EP4291243A1
(en)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
|
AU2022230795B2
(en)
|
2021-03-02 |
2025-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
|
US20240190874A1
(en)
|
2021-03-03 |
2024-06-13 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
|
WO2022187423A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Cereblon ligands
|
|
CN117677634A
(zh)
|
2021-03-05 |
2024-03-08 |
利达提斯有限公司 |
三聚体多肽及其在治疗癌症中的用途
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Cd3及びcldn6に結合するヘテロ二量体抗体
|
|
JP2024510989A
(ja)
|
2021-03-12 |
2024-03-12 |
メンドゥス・ベスローテン・フェンノートシャップ |
ワクチン接種方法及びcd47遮断薬の使用
|
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
|
US20240165094A1
(en)
|
2021-03-17 |
2024-05-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
WO2022194988A2
(en)
|
2021-03-19 |
2022-09-22 |
Heidelberg Pharma Research Gmbh |
B-lymphocyte specific amatoxin antibody conjugates
|
|
KR20230171435A
(ko)
|
2021-03-19 |
2023-12-20 |
트레인드 테라퓨틱스 디스커버리, 아이엔씨. |
훈련된 면역을 조절하기 위한 화합물 및 이의 사용 방법
|
|
KR20230159590A
(ko)
|
2021-03-23 |
2023-11-21 |
리제너론 파아마슈티컬스, 인크. |
Pd-1 억제제를 투여함에 의한 면역억제 또는 면역손상된 환자에서 암을 치료하는 방법
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
CA3213049A1
(en)
|
2021-03-25 |
2022-09-29 |
Laura E. BENJAMIN |
Targeted therapies in cancer
|
|
EP4313127A1
(en)
|
2021-03-29 |
2024-02-07 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
AU2022246895A1
(en)
|
2021-03-31 |
2023-10-19 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4314060A1
(en)
|
2021-03-31 |
2024-02-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202305009A
(zh)
|
2021-04-08 |
2023-02-01 |
美商默沙東有限責任公司 |
以皮下投予抗pd1抗體治療癌症之方法
|
|
JP2024514836A
(ja)
|
2021-04-08 |
2024-04-03 |
ニューリックス セラピューティクス,インコーポレイテッド |
Cbl-b阻害化合物との組み合わせ療法
|
|
AU2022253474A1
(en)
|
2021-04-08 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
GB2623199A
(en)
|
2021-04-08 |
2024-04-10 |
Marengo Therapeutics Inc |
Multifunctional molecules binding to TCR and uses thereof
|
|
TW202304999A
(zh)
|
2021-04-09 |
2023-02-01 |
美商思進公司 |
以抗tigit抗體治療癌症之方法
|
|
JP2024513575A
(ja)
|
2021-04-12 |
2024-03-26 |
インサイト・コーポレイション |
Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
|
|
MX2023012060A
(es)
|
2021-04-13 |
2024-01-22 |
Nuvalent Inc |
Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
|
|
CA3235132A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
MX2023012364A
(es)
|
2021-04-20 |
2023-11-01 |
Seagen Inc |
Modulacion de citotoxicidad celular dependiente de anticuerpos.
|
|
US20240158861A1
(en)
|
2021-04-23 |
2024-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
EP4329780B1
(en)
|
2021-04-29 |
2025-11-26 |
Yeda Research and Development Co. Ltd |
T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
|
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
|
US20220389089A1
(en)
|
2021-05-07 |
2022-12-08 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
WO2022238386A1
(en)
|
2021-05-10 |
2022-11-17 |
Institut Curie |
Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022242737A1
(zh)
|
2021-05-21 |
2022-11-24 |
天津立博美华基因科技有限责任公司 |
药物组合及其用途
|
|
AU2022281461A1
(en)
|
2021-05-25 |
2024-01-04 |
Edelweiss Immune Inc |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
|
CA3220191A1
(en)
|
2021-05-26 |
2022-12-01 |
Tania Crombet Ramos |
Use of therapeutic compositions for the treatment of patients with tumours of epithelial origin
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
TW202313679A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
KR20240049794A
(ko)
|
2021-06-07 |
2024-04-17 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
|
|
AR126101A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
|
WO2022261160A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
KR20240019111A
(ko)
|
2021-06-10 |
2024-02-14 |
오노 야꾸힝 고교 가부시키가이샤 |
Cd47 저해 물질, 면역 체크포인트 저해 물질 및 표준 요법의 병용에 의한 암 치료법
|
|
TW202317623A
(zh)
|
2021-06-14 |
2023-05-01 |
美商再生元醫藥公司 |
基於il2之治療劑及其使用方法
|
|
WO2022263632A1
(en)
|
2021-06-18 |
2022-12-22 |
Alligator Bioscience Ab |
Novel combination therapies and uses thereof
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
EP4363059A1
(en)
|
2021-06-29 |
2024-05-08 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
AU2022302143A1
(en)
|
2021-07-02 |
2024-01-18 |
Yale University |
Compositions and methods for treating cancers
|
|
CR20240059A
(es)
|
2021-07-07 |
2024-03-21 |
Incyte Corp |
Compuestos tricíclicos como inhibidores de kras.
|
|
EP4370552A1
(en)
|
2021-07-13 |
2024-05-22 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
US20230114765A1
(en)
|
2021-07-14 |
2023-04-13 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
US20230139492A1
(en)
|
2021-07-19 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
|
|
EP4377348A1
(en)
|
2021-07-30 |
2024-06-05 |
Seagen Inc. |
Treatment for cancer
|
|
IL309934A
(en)
|
2021-07-30 |
2024-03-01 |
Ona Therapeutics S L |
Anti-cd36 antibodies and their use to treat cancer
|
|
US20250215103A1
(en)
|
2021-08-03 |
2025-07-03 |
Hoffmann-La Roche Inc. |
Bispecific antibodies and methods of use
|
|
IL310550A
(en)
|
2021-08-04 |
2024-03-01 |
Univ Colorado Regents |
LAT-activating chimeric antigen receptor T cells and methods of using them
|
|
CA3227880A1
(en)
|
2021-08-05 |
2023-02-09 |
Marios SOTIROPOULOS |
Scanning dynamic device for minibeams production
|
|
WO2023028501A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
EP4395832A1
(en)
|
2021-08-31 |
2024-07-10 |
Yale University |
Compositions and methods for treating cancers
|
|
CN118043352A
(zh)
|
2021-09-02 |
2024-05-14 |
德国癌症研究中心公共法律基金会 |
副作用减少的抗cecam6抗体
|
|
WO2023034530A1
(en)
|
2021-09-02 |
2023-03-09 |
Teon Therapeutics, Inc. |
Methods of improving growth and function of immune cells
|
|
US20240376100A1
(en)
|
2021-09-08 |
2024-11-14 |
Redona Therapeutics, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives
|
|
US20240316061A1
(en)
|
2021-09-17 |
2024-09-26 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
JP2024537824A
(ja)
|
2021-10-01 |
2024-10-16 |
インサイト・コーポレイション |
ピラゾロキノリンkras阻害剤
|
|
IL311790A
(en)
|
2021-10-05 |
2024-05-01 |
Chang Hao Ming |
Natural killer cells and methods of use thereof
|
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
|
EP4413040A1
(en)
|
2021-10-06 |
2024-08-14 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
JP2024537096A
(ja)
*
|
2021-10-14 |
2024-10-10 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための代替的なPD1-IL7vイムノコンジュゲート
|
|
WO2023064857A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
|
IL311837A
(en)
|
2021-10-20 |
2024-05-01 |
Takeda Pharmaceuticals Co |
Compositions targeting bcma and methods of use thereof
|
|
WO2023066322A1
(zh)
|
2021-10-21 |
2023-04-27 |
杭州阿诺生物医药科技有限公司 |
一种融合多肽及其用途
|
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
AU2022377637A1
(en)
|
2021-10-28 |
2024-05-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
IL309227A
(en)
|
2021-10-29 |
2024-02-01 |
Bristol Myers Squibb Co |
LAG-3 antagonist therapy for hematological cancer
|
|
MX2024005080A
(es)
|
2021-10-29 |
2024-05-13 |
Seagen Inc |
Metodos para tratar cancer con una combinacion de un anticuerpo anti-pd-1 y un conjugado de anticuerpo anti-cd30-farmaco.
|
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
|
EP4427044A1
(en)
|
2021-11-03 |
2024-09-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
WO2023084445A1
(en)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Combination therapy for treating lung cancer
|
|
WO2023083379A1
(zh)
|
2021-11-15 |
2023-05-19 |
中国科学院生物物理研究所 |
一种以白介素15为活性成份的融合蛋白构建体及其应用
|
|
US20250019708A1
(en)
|
2021-11-19 |
2025-01-16 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
|
KR20240122783A
(ko)
|
2021-11-22 |
2024-08-13 |
인사이트 코포레이션 |
Fgfr 저해제 및 kras 저해제를 포함하는 병용 요법
|
|
WO2023097211A1
(en)
|
2021-11-24 |
2023-06-01 |
The University Of Southern California |
Methods for enhancing immune checkpoint inhibitor therapy
|
|
US20230203010A1
(en)
|
2021-12-03 |
2023-06-29 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
|
TW202328438A
(zh)
|
2021-12-08 |
2023-07-16 |
新加坡商泰莎治療有限公司 |
淋巴瘤之治療
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
|
CN118660964A
(zh)
|
2021-12-16 |
2024-09-17 |
瓦莱里奥治疗公司 |
新型缀合核酸分子及其用途
|
|
EP4452327A1
(en)
|
2021-12-20 |
2024-10-30 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
US20250041261A1
(en)
|
2021-12-21 |
2025-02-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
AR128043A1
(es)
|
2021-12-22 |
2024-03-20 |
Incyte Corp |
Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación
|
|
KR20240130705A
(ko)
|
2021-12-30 |
2024-08-29 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
|
|
JP2025502061A
(ja)
|
2022-01-07 |
2025-01-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
再発性卵巣癌を、二重特異性抗muc16×抗cd3抗体単独で、または抗pd-1抗体と組み合わせて治療する方法
|
|
US20250215076A1
(en)
|
2022-01-26 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
TWI864587B
(zh)
|
2022-02-14 |
2024-12-01 |
美商基利科學股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
|
WO2023159102A1
(en)
|
2022-02-17 |
2023-08-24 |
Regeneron Pharmaceuticals, Inc. |
Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
|
|
EP4482947A1
(en)
|
2022-02-24 |
2025-01-01 |
Amazentis SA |
Uses of urolithins
|
|
MX2024010310A
(es)
|
2022-02-25 |
2024-08-28 |
Bristol Myers Squibb Co |
Terapia de combinacion para carcinoma colorrectal.
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
IL314840A
(en)
|
2022-03-07 |
2024-10-01 |
Mabxience Res S L |
Stable Antibody Formulations
|
|
PE20250667A1
(es)
|
2022-03-07 |
2025-03-04 |
Incyte Corp |
Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2
|
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
|
EP4491194A4
(en)
|
2022-03-10 |
2025-12-31 |
Genexine Inc |
TRIPLE COMBINATION DRUG DOSAGE THERAPY FOR THE TREATMENT OF HEAD AND NECK CANCER
|
|
US20250195645A1
(en)
|
2022-03-16 |
2025-06-19 |
Daiichi Sankyo Company, Limited |
Combination of multispecific molecule and immune checkpoint inhibitor
|
|
AU2023236126A1
(en)
|
2022-03-17 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
KR20240159621A
(ko)
|
2022-03-18 |
2024-11-05 |
브리스톨-마이어스 스큅 컴퍼니 |
폴리펩티드를 단리하는 방법
|
|
JP2025510795A
(ja)
|
2022-03-24 |
2025-04-15 |
アンスティテュ・クリー |
神経膠芽腫における腫瘍転位因子由来のネオ抗原ペプチドを標的化する免疫療法
|
|
US20250213614A1
(en)
|
2022-03-31 |
2025-07-03 |
Institut Curie |
Modified RELA Protein for Inducing Interferon Expression and Engineered Immune Cells with Improved Interferon Expression
|
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2023194608A1
(en)
|
2022-04-07 |
2023-10-12 |
Institut Curie |
Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
|
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
|
WO2023194607A1
(en)
|
2022-04-07 |
2023-10-12 |
Institut Curie |
Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
|
|
CN119731651A
(zh)
|
2022-04-08 |
2025-03-28 |
百时美施贵宝公司 |
三级淋巴结构的机器学习标识、分类和量化
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
EP4514382A1
(en)
|
2022-04-28 |
2025-03-05 |
Musc Foundation for Research Development |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
TW202413412A
(zh)
|
2022-05-12 |
2024-04-01 |
丹麥商珍美寶股份有限公司 |
在組合療法中能夠結合到cd27之結合劑
|
|
EP4525992A1
(en)
|
2022-05-16 |
2025-03-26 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
|
WO2023230554A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
|
|
WO2023230128A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
EP4532010A1
(en)
|
2022-05-27 |
2025-04-09 |
Takeda Pharmaceutical Company Limited |
Dosing of cd38-binding fusion protein
|
|
JP2025518785A
(ja)
|
2022-06-02 |
2025-06-19 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗体組成物及びその使用方法
|
|
TW202412744A
(zh)
|
2022-06-07 |
2024-04-01 |
瑞士商意梭凱普公司 |
包括應用在食道黏膜之藥劑的藥物遞送系統及其應用
|
|
JP2025523403A
(ja)
|
2022-06-08 |
2025-07-23 |
タイダル・セラビューティクス・インコーポレイテッド |
イオン化可能なカチオン性脂質及び脂質ナノ粒子、並びにその合成方法及び使用
|
|
UY40305A
(es)
|
2022-06-08 |
2023-12-29 |
Incyte Corp |
Compuestos tricíclicos de triazolo como inhibidores de dgk
|
|
JP2025523424A
(ja)
|
2022-06-16 |
2025-07-23 |
ランカプ バイオ ベータ リミテッド |
Ceacam5およびcd47に対する二重特異性抗体ならびにceacam5およびcd3に対する二重特異性抗体の併用療法
|
|
CN119731204A
(zh)
|
2022-06-16 |
2025-03-28 |
赛福伦有限责任公司 |
抗pd-1抗体-衰减的il-2免疫偶联物及其用途
|
|
KR20250029137A
(ko)
|
2022-06-22 |
2025-03-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법
|
|
TW202413359A
(zh)
|
2022-06-22 |
2024-04-01 |
美商英塞特公司 |
雙環胺cdk12抑制劑
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
KR20250034101A
(ko)
|
2022-07-01 |
2025-03-10 |
트랜스진 |
계면활성제-단백질-d 및 tnfsf의 구성원을 포함하는 융합 단백질
|
|
WO2024015731A1
(en)
|
2022-07-11 |
2024-01-18 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
JP2025524620A
(ja)
|
2022-07-11 |
2025-07-30 |
オートノマス セラピューティクス,インコーポレイティド |
暗号化rna及びその使用方法
|
|
EP4554943A1
(en)
|
2022-07-14 |
2025-05-21 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
|
EP4310197A1
(en)
|
2022-07-21 |
2024-01-24 |
Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda |
Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
|
|
WO2024026253A1
(en)
*
|
2022-07-25 |
2024-02-01 |
Agensys, Inc. |
Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab
|
|
CN119923267A
(zh)
|
2022-07-27 |
2025-05-02 |
阿斯利康(瑞典)有限公司 |
表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合
|
|
TW202412859A
(zh)
|
2022-07-28 |
2024-04-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及雙特異性檢查點抑制劑之組合
|
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
JP2025530983A
(ja)
|
2022-08-02 |
2025-09-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
二重特異性抗psma×抗cd28抗体を抗pd-1抗体と組み合わせて、転移性去勢抵抗性前立腺癌を治療する方法
|
|
WO2024028386A1
(en)
|
2022-08-02 |
2024-02-08 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
|
JP2025525937A
(ja)
|
2022-08-05 |
2025-08-07 |
ジュノー セラピューティクス インコーポレイテッド |
Gprc5dおよびbcmaに特異的なキメラ抗原受容体
|
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
|
JP2025527578A
(ja)
|
2022-08-18 |
2025-08-22 |
パルマトリックス オペレーティング カンパニー,インコーポレイテッド |
吸入用血管新生阻害剤を用いてがんを治療する方法
|
|
EP4578876A1
(en)
|
2022-08-23 |
2025-07-02 |
ONO Pharmaceutical Co., Ltd. |
Bispecific antibody
|
|
EP4548937A1
(en)
|
2022-08-26 |
2025-05-07 |
Eisai R&D Management Co., Ltd. |
Antibody-drug complex
|
|
WO2024054418A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Cugene Inc. |
Sequence optimization of a pd1 blocking antibody
|
|
WO2024056716A1
(en)
|
2022-09-14 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
|
WO2024068617A1
(en)
|
2022-09-26 |
2024-04-04 |
Institut Curie |
Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
|
|
CN120379691A
(zh)
|
2022-09-30 |
2025-07-25 |
爱兰蒂斯疗法股份公司 |
耐药性肝细胞癌的治疗
|
|
KR20250099774A
(ko)
|
2022-10-03 |
2025-07-02 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 egfr x cd28 항체를 단독으로 또는 항-pd-1 항체와 조합하여 사용하여 암을 치료하는 방법
|
|
EP4598946A1
(en)
|
2022-10-05 |
2025-08-13 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
JP7730432B2
(ja)
|
2022-10-19 |
2025-08-27 |
アステラス製薬株式会社 |
がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用
|
|
EP4604939A1
(en)
|
2022-10-20 |
2025-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination therapy for the treatment of cancer
|
|
EP4605422A2
(en)
|
2022-10-20 |
2025-08-27 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
|
EP4608390A1
(en)
|
2022-10-24 |
2025-09-03 |
Cancer Research Technology Limited |
Tumour sensitisation to checkpoint inhibitors with redox status modifier
|
|
WO2024089417A1
(en)
|
2022-10-24 |
2024-05-02 |
Memorial Sloan-Kettering Cancer Center |
Tumour stratification for responsiveness to an immune checkpoint inhibitor
|
|
CN116041539B
(zh)
*
|
2022-10-31 |
2023-07-21 |
山东博安生物技术股份有限公司 |
Il-2突变体免疫缀合物
|
|
EP4611897A1
(en)
|
2022-11-01 |
2025-09-10 |
Heidelberg Pharma Research GmbH |
Anti-gucy2c antibody and uses thereof
|
|
EP4615485A1
(en)
|
2022-11-07 |
2025-09-17 |
NeoImmuneTech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
TW202428272A
(zh)
|
2022-11-18 |
2024-07-16 |
美商英塞特公司 |
作為dgk抑制劑之雜芳基氟烯烴
|
|
CN120584182A
(zh)
|
2022-11-21 |
2025-09-02 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞扩增的二维过程及其疗法
|
|
WO2024110905A1
(en)
|
2022-11-24 |
2024-05-30 |
Beigene, Ltd. |
Anti-cea antibody drug conjugates and methods of use
|
|
EP4613780A4
(en)
|
2022-11-29 |
2025-12-31 |
Adlai Nortye Biopharma Co Ltd |
Fusion Polypeptide and its Use
|
|
AU2023402712A1
(en)
|
2022-12-01 |
2025-05-08 |
Innate Pharma |
Compositions and methods for neoadjuvant treatment in cancer comprising anti-cd39 antibodies
|
|
EP4626446A1
(en)
|
2022-12-01 |
2025-10-08 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
|
CN120390652A
(zh)
|
2022-12-01 |
2025-07-29 |
免疫医疗有限公司 |
用于治疗癌症的包含抗pd-l1抗体和抗cd73抗体的组合疗法
|
|
JP2026500503A
(ja)
|
2022-12-13 |
2026-01-07 |
ジュノー セラピューティクス インコーポレイテッド |
Baff-rおよびcd19に特異的なキメラ抗原受容体、ならびにその方法および使用
|
|
CN120418289A
(zh)
|
2022-12-14 |
2025-08-01 |
安斯泰来制药欧洲有限公司 |
结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
|
|
KR20250123912A
(ko)
|
2022-12-21 |
2025-08-18 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 병용 요법
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
|
US20240270739A1
(en)
|
2023-01-12 |
2024-08-15 |
Incyte Corporation |
Heteroaryl Fluoroalkenes As DGK Inhibitors
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
CN121293352A
(zh)
|
2023-01-19 |
2026-01-09 |
广州百济神州生物制药有限公司 |
抗cmet抗体及使用方法
|
|
AR131654A1
(es)
|
2023-01-20 |
2025-04-16 |
Boehringer Ingelheim Int |
PROTEÍNAS DE FUSIÓN Fc DE IL-12
|
|
KR20250140097A
(ko)
|
2023-01-30 |
2025-09-24 |
키맵 리미티드 |
항체
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
AU2024225483A1
(en)
|
2023-02-23 |
2025-08-28 |
Imcheck Therapeutics |
Combination of btn3a activating antibody and immune checkpoint inhibitors
|
|
AR132064A1
(es)
|
2023-03-06 |
2025-05-21 |
Beigene Switzerland Gmbh |
Anticuerpos anti-cldn6 y métodos de uso
|
|
TW202436353A
(zh)
|
2023-03-06 |
2024-09-16 |
瑞士商百濟神州瑞士有限責任公司 |
抗cldn6與抗cd3多重特異性抗體以及使用方法
|
|
TW202436345A
(zh)
|
2023-03-06 |
2024-09-16 |
瑞士商百濟神州瑞士有限責任公司 |
抗cd3多特異性抗體及使用方法
|
|
WO2024184417A1
(en)
|
2023-03-07 |
2024-09-12 |
Photocure Asa |
Therapy for bladder cancer
|
|
CN121127264A
(zh)
|
2023-03-13 |
2025-12-12 |
瑞泽恩制药公司 |
用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合
|
|
EP4680285A1
(en)
|
2023-03-13 |
2026-01-21 |
Heidelberg Pharma Research GmbH |
Subcutaneously administered antibody-drug conjugates for use in cancer treatment
|
|
EP4680269A1
(en)
|
2023-03-13 |
2026-01-21 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Composition of selected tumor infiltrating lymphocytes and related methods of producing and using the same
|
|
EP4680635A1
(en)
|
2023-03-13 |
2026-01-21 |
F. Hoffmann-La Roche AG |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024194401A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Vps4b inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194402A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194673A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Methods for the treatment of dedifferentiated liposarcoma
|
|
EP4683948A1
(en)
|
2023-03-21 |
2026-01-28 |
Biograph 55, Inc. |
Cd19/cd38 multispecific antibodies
|
|
WO2024200571A1
(en)
|
2023-03-28 |
2024-10-03 |
Institut National de la Santé et de la Recherche Médicale |
Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
|
|
IL320593A
(en)
|
2023-03-29 |
2025-07-01 |
Daiichi Sankyo Co Ltd |
Anti-CD25 antibody and anti-CD25 antibody conjugate
|
|
WO2024206357A1
(en)
|
2023-03-29 |
2024-10-03 |
Merck Sharp & Dohme Llc |
Il4i1 inhibitors and methods of use
|
|
WO2024209072A1
(en)
|
2023-04-06 |
2024-10-10 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
|
WO2024215787A1
(en)
|
2023-04-11 |
2024-10-17 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating osteosarcoma using lair1 binding agents and pd-1 antagonists
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024213533A1
(en)
|
2023-04-13 |
2024-10-17 |
Alligator Bioscience Ab |
Combination therapies
|
|
WO2024213782A1
(en)
|
2023-04-13 |
2024-10-17 |
Institut Curie |
Methods for the treatment of t-cell acute lymphoblastic leukemia
|
|
WO2024220645A1
(en)
|
2023-04-18 |
2024-10-24 |
Incyte Corporation |
2-azabicyclo[2.2.1]heptane kras inhibitors
|
|
US20240390340A1
(en)
|
2023-04-18 |
2024-11-28 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
WO2024223299A2
(en)
|
2023-04-26 |
2024-10-31 |
Isa Pharmaceuticals B.V. |
Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
|
|
WO2024228167A1
(en)
|
2023-05-03 |
2024-11-07 |
Iox Therapeutics Inc. |
Inkt cell modulator liposomal compositions and methods of use
|
|
TW202509069A
(zh)
|
2023-05-04 |
2025-03-01 |
美商諾瓦森塔股份有限公司 |
抗cd161抗體及其使用方法
|
|
WO2024231384A1
(en)
|
2023-05-10 |
2024-11-14 |
Institut National de la Santé et de la Recherche Médicale |
Compositions for treating senescence related disease
|
|
TW202509071A
(zh)
|
2023-05-12 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
能夠與ox40結合之抗體、其變異體及其用途
|
|
WO2024236048A1
(en)
|
2023-05-16 |
2024-11-21 |
Nh Theraguix |
Combination therapy for treating tumors with radiotherapy
|
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
|
WO2024261239A1
(en)
|
2023-06-23 |
2024-12-26 |
Imcheck Therapeutics |
Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
|
|
WO2025006811A1
(en)
|
2023-06-27 |
2025-01-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
WO2025002263A1
(zh)
|
2023-06-30 |
2025-01-02 |
默沙东有限责任公司 |
治疗组合及其用途和治疗方法
|
|
AU2024311205A1
(en)
|
2023-06-30 |
2026-01-22 |
Merck Sharp & Dohme Llc |
Treatment method and use of pharmaceutical combination containing conjugate
|
|
CA3221817A1
(en)
*
|
2023-06-30 |
2025-06-13 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Combination therapies for the treatment of cancer
|
|
IL304887A
(en)
|
2023-07-31 |
2025-02-01 |
Yeda Res & Dev |
T-cell receptor directed against RAS neoantigen
|
|
WO2025030044A1
(en)
|
2023-08-02 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025030041A1
(en)
|
2023-08-02 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025034883A1
(en)
|
2023-08-08 |
2025-02-13 |
Quanta Therapeutics, Inc. |
Combination therapies with kras modulators
|
|
US20250099605A1
(en)
|
2023-08-15 |
2025-03-27 |
Gilead Sciences, Inc. |
Treatment of non-small cell lung cancer using sacituzumab govitecan and an anti-pd-1 antibody or antigen binding fragment thereof
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
TW202517247A
(zh)
|
2023-08-24 |
2025-05-01 |
美商英塞特公司 |
雙環dgk抑制劑
|
|
WO2025049858A1
(en)
|
2023-09-01 |
2025-03-06 |
Amgen Inc. |
Molecules for treatment of cancer
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
WO2025051895A1
(en)
|
2023-09-06 |
2025-03-13 |
Novimmune Sa |
Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025068393A1
(en)
|
2023-09-27 |
2025-04-03 |
Institut Curie |
Methods for the treatment of fibrotic related diseases
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
CN119823281A
(zh)
*
|
2023-10-08 |
2025-04-15 |
广东菲鹏制药股份有限公司 |
抗pd1-il10融合蛋白及其应用
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
US20250114468A1
(en)
|
2023-10-09 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
|
|
WO2025080865A1
(en)
|
2023-10-11 |
2025-04-17 |
Turnstone Biologics Corp. |
Combination of tumor infiltrating lymphocytes (til) and low dose radiation
|
|
TW202515903A
(zh)
|
2023-10-12 |
2025-04-16 |
瑞士商百濟神州瑞士有限責任公司 |
手術前後基於抗pd-1之治療
|
|
WO2025078632A1
(en)
|
2023-10-12 |
2025-04-17 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from cancer
|
|
WO2025081075A1
(en)
|
2023-10-13 |
2025-04-17 |
Gilead Sciences, Inc. |
Combination therapies for treating cancers
|
|
WO2025096638A2
(en)
|
2023-10-30 |
2025-05-08 |
Turnstone Biologics Corp. |
Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
|
|
WO2025096738A1
(en)
|
2023-11-01 |
2025-05-08 |
Incyte Corporation |
Kras inhibitors
|
|
WO2025093824A1
(en)
|
2023-11-02 |
2025-05-08 |
Tilt Biotherapeutics Oy |
Oncolytic adenovirus, immune checkpoint inhibitor and chemoterapeutic agent combination therapy of cancer
|
|
WO2025096843A1
(en)
|
2023-11-03 |
2025-05-08 |
Amgen Inc. |
Bispecific molecules
|
|
WO2025106736A2
(en)
|
2023-11-15 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
|
|
WO2025106905A1
(en)
|
2023-11-17 |
2025-05-22 |
Quanta Therapeutics, Inc. |
Combination therapies with a kras modulator and an immunomodulator inhibitor
|
|
WO2025109597A1
(en)
|
2023-11-22 |
2025-05-30 |
Yeda Research And Development Co. Ltd. |
T cell receptors directed against androgen receptor mutation
|
|
TW202539732A
(zh)
|
2023-11-29 |
2025-10-16 |
美商再生元醫藥公司 |
以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ox40之抗體
|
|
TW202523667A
(zh)
|
2023-12-05 |
2025-06-16 |
美商英塞特公司 |
作為dgk抑制劑之三環三唑并化合物
|
|
TW202523304A
(zh)
|
2023-12-06 |
2025-06-16 |
美商英塞特公司 |
包含dgk抑制劑及pd—1/pd—l1抑制劑之組合療法
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025128652A1
(en)
|
2023-12-12 |
2025-06-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating endometrial cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
WO2025128465A1
(en)
*
|
2023-12-12 |
2025-06-19 |
Merck Sharp & Dohme Llc |
Methods of purifying anti-pd-1 antibodies or antigen-binding fragments thereof using mixed-mode anion-exchange chromatography
|
|
US20250195536A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|
|
WO2025132479A1
(en)
|
2023-12-18 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Flt3 inhibitor for modulating macrophages polarization
|
|
US20250195677A1
(en)
|
2023-12-19 |
2025-06-19 |
Cephalon Llc |
Uses for attenuated il-2 immunoconjugates
|
|
WO2025132695A1
(en)
|
2023-12-19 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Recombinant rhabdovirus encoding for a gasdermin
|
|
WO2025133175A1
(en)
|
2023-12-21 |
2025-06-26 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
EP4574165A1
(en)
|
2023-12-21 |
2025-06-25 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025132770A1
(en)
|
2023-12-22 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Affitins for the treatment of cancer
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
US20250222125A1
(en)
|
2024-01-05 |
2025-07-10 |
Beigene, Ltd. |
Anti-FGFR2b Antibodies, Conjugates and Methods of Use
|
|
WO2025151487A2
(en)
|
2024-01-08 |
2025-07-17 |
Regents Of The University Of Michigan |
Small-molecule inhibitors of adar1
|
|
WO2025151800A1
(en)
|
2024-01-10 |
2025-07-17 |
Autonomous Therapeutics, Inc. |
Programmable, rna editor-controlled nucleic acid dose amplifiers and their methods of use
|
|
WO2025151803A1
(en)
|
2024-01-10 |
2025-07-17 |
Autonomous Therapeutics, Inc. |
Alphaviral encrypted rnas and their methods of use
|
|
WO2025153834A1
(en)
|
2024-01-19 |
2025-07-24 |
Institut National de la Santé et de la Recherche Médicale |
Methods of predicting the risk of recurrence and/or death of patients suffering from a hepatocellular carcinoma (hcc)
|
|
WO2025158077A1
(en)
|
2024-01-26 |
2025-07-31 |
Institut Curie |
Lipid degraders to trigger ferroptosis in cancer
|
|
WO2025163468A1
(en)
|
2024-01-30 |
2025-08-07 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2025170888A1
(en)
|
2024-02-05 |
2025-08-14 |
Signalchem Lifesciences Corporation |
A combination of the axl inhibitor slc-391 and a pd-1 inhibitor for use in the treatment of blood cancer
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
EP4658320A1
(en)
|
2024-02-27 |
2025-12-10 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
WO2025191529A1
(en)
|
2024-03-14 |
2025-09-18 |
Biohaven Therapeutics Ltd. |
Next generation riluzole prodrugs
|
|
WO2025207705A1
(en)
|
2024-03-26 |
2025-10-02 |
Amgen Inc. |
Cancer treatments using mta-cooperative prmt5 inhibitors
|
|
WO2025202213A1
(en)
|
2024-03-26 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
|
|
WO2025203012A1
(en)
|
2024-03-27 |
2025-10-02 |
Novartis Ag |
Kras g12c inhibitor for use for the treatment of non-small cell lung cancer
|
|
WO2025202971A1
(en)
|
2024-03-27 |
2025-10-02 |
Novartis Ag |
Kras g12c inhibitor for use for the treatment of non-small cell lung cancer
|
|
WO2025202450A1
(en)
|
2024-03-28 |
2025-10-02 |
Institut Curie |
Myeloid cells modified by cytokine chimeric receptor and uses thereof
|
|
EP4624494A1
(en)
|
2024-03-29 |
2025-10-01 |
Institut Curie |
Her2 single domain antibody and uses thereof
|
|
WO2025210123A1
(en)
|
2024-04-03 |
2025-10-09 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating cancers
|
|
WO2025213154A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
|
|
WO2025210252A1
(en)
|
2024-04-05 |
2025-10-09 |
Institut Curie |
Modulators of fam118b protein for use in therapy
|
|
WO2025219330A1
(en)
|
2024-04-15 |
2025-10-23 |
Institut National de la Santé et de la Recherche Médicale |
Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
|
|
WO2025219595A1
(en)
|
2024-04-19 |
2025-10-23 |
Biper Therapeutics |
Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
|
|
WO2025223372A1
(en)
|
2024-04-22 |
2025-10-30 |
Fujian Haixi Pharmaceuticals Co., Ltd. |
Combination comprising a pd-1 inhibitor and a pyridine compound for use in treating solid tumors
|
|
WO2025228998A1
(en)
|
2024-04-30 |
2025-11-06 |
Institut National de la Santé et de la Recherche Médicale |
Use of hdac4 inhibitors for the treatment of melanoma
|
|
WO2025233224A1
(en)
|
2024-05-09 |
2025-11-13 |
F. Hoffmann-La Roche Ag |
Use of atr inhibitors in combination with anti-pd(l)1 therapy
|
|
WO2025232879A1
(en)
|
2024-05-10 |
2025-11-13 |
Cytocares (Shanghai) Inc. |
Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025245256A1
(en)
|
2024-05-22 |
2025-11-27 |
Tizona Therapeutics, Inc. |
Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies
|
|
WO2025242910A1
(en)
|
2024-05-23 |
2025-11-27 |
Egle Therapeutics |
Il18r agonist antibodies and uses thereof
|
|
EP4653460A1
(en)
|
2024-05-23 |
2025-11-26 |
Egle Therapeutics |
Il18r agonist antibodies and uses thereof
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
WO2025247829A1
(en)
|
2024-05-27 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating prostate cancer
|
|
WO2025248505A1
(en)
|
2024-05-31 |
2025-12-04 |
Wayne State University |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
WO2025252855A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
|
|
WO2025252857A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
Il-15 muteins with ph-dependent binding for il-15ralpha
|
|
WO2025257220A1
(en)
|
2024-06-10 |
2025-12-18 |
Merck Patent Gmbh |
Muc-1 conditional cd40 agonists
|
|
WO2025257588A1
(en)
|
2024-06-10 |
2025-12-18 |
Affimed Gmbh |
Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
|
|
WO2025259515A2
(en)
|
2024-06-11 |
2025-12-18 |
Amgen Inc. |
Combination treatment
|
|
GB202408360D0
(en)
|
2024-06-11 |
2024-07-24 |
Cancer Research Tech Ltd |
Tumour sensitisation
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026006604A1
(en)
|
2024-06-26 |
2026-01-02 |
Lyell Immunopharma, Inc. |
Feeder cell replacement
|
|
WO2026015612A1
(en)
|
2024-07-10 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating smarcb1-deficient cancers
|
|
WO2026017820A1
(en)
|
2024-07-18 |
2026-01-22 |
Egle Therapeutics |
Fusion protein for cancer treatment
|
|
EP4681780A1
(en)
|
2024-07-18 |
2026-01-21 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|